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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 66, Revision 1 
(FGE.66Rev1): 
Consideration of Furfuryl Alcohol and Related Flavouring Substances 
Evaluated by JECFA (55th meeting)1 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and 
Processing Aids (CEF)2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European 
Food Safety Authority was requested to evaluate 14 flavouring substances in the Revision 1 of 
Flavouring Group Evaluation 66, using the Procedure in Commission Regulation (EC) No 1565/2000. 
None of the substances were considered to have genotoxic potential. The substances were evaluated 
through a stepwise approach (the Procedure) that integrates information on structure-activity 
relationships, intake from current uses, toxicological threshold of concern, and available data on 
metabolism and toxicity. The Panel concluded that the 14 substances [FL-no: 13.001, 13.002, 13.003, 
13.005, 13.018, 13.019, 13.025, 13.038, 13.057, 13.062, 13.067, 13.068, 13.073 and 13.128] do not 
give rise to safety concerns at their levels of dietary intake, estimated on the basis of the MSDI 
approach. 
© European Food Safety Authority, 2011 
                                                     
 
1  On request from the Commission, Question No EFSA-Q-2011-00863,  EFSA-Q-2011-00864, EFSA-Q-2011-00865, 
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SUMMARY  
The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (the Panel) to provide scientific advice to the Commission on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was requested to consider the Joint FAO/WHO Expert 
Committee on Food Additives (the JECFA) evaluations of flavouring substances assessed since 2000, 
and to decide whether no further evaluation is necessary, as laid down in Commission Regulation (EC) 
No 1565/2000. These flavouring substances are listed in the Register, which was adopted by 
Commission Decision 1999/217/EC and its consecutive amendments. 
The JECFA has evaluated 15 furfuryl alcohol derivatives at their 55th meeting. The Panel concluded 
that 14 substances in Flavouring Group Evaluation 66 (FGE.66) are structurally related to the 
subgroup of 10 furfuryl derivatives in the group of furfuryl and furan derivatives with and without 
additional side-chain substituents and heteroatoms evaluated by EFSA in FGE.13, Revision 2 
(FGE.13Rev2). The 15th substance, 2-Benzofurancarboxaldehyde [FL-no: 13.031], is considered too 
structurally different from the other 14 to be included in the present FGE. This substance will be 
evaluated in FGE.67Rev1. 
Eight of the candidate substances in this FGE are alpha,beta-unsaturated aldehydes or precursors for 
such which is a structural alert for genotoxicity. These eight substances [FL-no: 13.001, 13.018, 
13.019, 13.057, 13.062, 13.067, 13.068 and 13.128] have initially been considered with respect to 
genotoxicity. The Panel concluded that for all eight substances the genotoxicity data available do not 
preclude their evaluation through the Procedure. No concern for genotoxicity was identified for the 
remaining six substances without the alpha,beta structural alert [FL-no: 13.002, 13.003, 13.005, 
13.025, 13.038 and 13.073].  
The Panel agrees with the application of the Procedure as performed by the JECFA for 13 substances 
considered in this FGE [FL-no: 13.002, 13.003, 13.005, 13.018, 13.019, 13.025, 13.038, 13.057, 
13.062, 13.067, 13.068, 13.073 and 13.128]. In contrast to the JECFA, the Panel evaluated the 
fourteenth substance [FL-no: 13.001] by comparison with a Benchmark Dose, Lower Confidence 
Limit (BMDL) for a metabolite (5-hydroxymethylfurfural; [FL-no: 13.139]). For none of the candidate 
substances in this FGE a safety concern was identified. 
For one substance, furfural [FL-no: 13.018], use levels have been provided by Industry and an 
mTAMDI figure of 9700 microgram/person/day could be calculated. For the remaining 13 substances 
[FL-no: 13.001, 13.002, 13.003, 13.005, 13.019, 13.025, 13.038, 13.057, 13.062, 13.067, 13.068, 
13.073 and 13.128] use levels are needed to calculate the mTAMDIs in order to identify those 
flavouring substances that need more refined exposure assessment and to finalise the evaluation.  
Adequate specifications including purity criteria and identity test are available for all 14 JECFA 
evaluated substances considered in the present FGE. 
Thus, for all 14 JECFA evaluated furfuryl derivatives [FL-no: 13.001, 13.002, 13.003, 13.005, 13.018, 
13.019, 13.025, 13.038, 13.057, 13.062, 13.067, 13.068, 13.073 and 13.128] the Panel agrees with the 
JECFA conclusion “No safety concern at estimated levels of intake as flavouring substances” based on 
the MSDI approach. 
KEY WORDS 
Alpha,beta-unsaturated aldehydes, furfural, furfuryl derivatives, furfuryl alcohol, flavouring 
substances, safety evaluation, FGE.66, FGE.66Rev1. 
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BACKGROUND 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996a) lays down a 
Procedure for the establishment of a list of flavouring substances, the use of which will be authorised 
to the exclusion of all other substances in the EU. In application of that Regulation, a Register of 
flavouring substances used in or on foodstuffs in the Member States was adopted by Commission 
Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 2009/163/EC (EC, 
2009a). Each flavouring substance is attributed a FLAVIS-number (FL-number) and all substances are 
divided into 34 chemical groups. Substances within a group should have some metabolic and 
biological behaviour in common. 
Substances which are listed in the Register are to be evaluated according to the evaluation programme 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a), which is broadly based on the 
Opinion of the Scientific Committee on Food (SCF, 1999a).  
Commission Regulation (EC) No 1565/2000 lays down that substances that are contained in the 
Register and will be classified in the future by the Joint FAO/WHO Expert Committee on Food 
Additives (the JECFA) so as to present no safety concern at current levels of intake will be considered 
by the European Food Safety Authority (EFSA), who may then decide that no further evaluation is 
necessary. 
In the period 2000 - 2008, during its 55th, 57th, 59th, 61st, 63rd, 65th, 68th and 69th meetings, the JECFA 
evaluated about 1000 substances, which are in the EU Register. 
TERMS OF REFERENCE 
EFSA is requested to consider the JECFA evaluations of flavouring substances assessed since 2000, 
and to decide whether no further evaluation is necessary, as laid down in Commission Regulation (EC) 
No 1565/2000 (EC, 2000a). These flavouring substances are listed in the Register which was adopted 
by Commission Decision 1999/217 EC (EC, 1999a) and its consecutive amendments. 
After the finalisation of the evaluation programme 31 December 2009, in their letter of the 11 
September 2009, the Commission requested EFSA to carry out a re-evaluation of 5-methylfurfural 
[FL-no: 13.001] in accordance with Commission Regulation (EC) No 1565/2000 (EC, 2000a).  
ASSESSMENT 
The approach used by EFSA for safety evaluation of flavouring substances is referred to in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a), hereafter named the “EFSA Procedure”. 
This Procedure is based on the Opinion of the Scientific Committee on Food (SCF, 1999a), which has 
been derived from the evaluation procedure developed by the Joint FAO/WHO Expert Committee on 
Food Additives (JECFA, 1995; JECFA, 1996a; JECFA, 1997a; JECFA, 1999b), hereafter named the 
“JECFA Procedure”. The Panel on Food Contact Materials, Enzymes, Flavourings and Processing 
Aids (the Panel) compares the JECFA evaluation of structurally related substances with the result of a 
corresponding EFSA evaluation, focussing on specifications, intake estimations and toxicity data, 
especially genotoxicity data. The evaluations by EFSA will conclude whether the flavouring 
substances are of no safety concern at their estimated levels of intake, whether additional data are 
required or whether certain substances should not be put through the EFSA Procedure. 
The following issues are of special importance. 
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Intake 
In its evaluation, the Panel as a default uses the “Maximised Survey-derived Daily Intake” (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe.  
In its evaluation, the JECFA includes intake estimates based on the MSDI approach derived from both 
European and USA production figures. The highest of the two MSDI figures is used in the evaluation 
by the JECFA. It is noted that in several cases, only the MSDI figures from the USA were available, 
meaning that certain flavouring substances have been evaluated by the JECFA only on the basis of 
these figures. For Register substances for which this is the case the Panel will need EU production 
figures in order to finalise the evaluation. 
When the Panel examined the information provided by the European Flavour Industry on the use 
levels in various foods, it appeared obvious that the MSDI approach in a number of cases would 
grossly underestimate the intake by regular consumers of products flavoured at the use level reported 
by the Industry, especially in those cases where the annual production values were reported to be 
small. In consequence, the Panel had reservations about the data on use and use levels provided and 
the intake estimates obtained by the MSDI approach. It is noted that the JECFA, at its 65th meeting 
considered ”how to improve the identification and assessment of flavouring agents, for which the 
MSDI estimates may be substantially lower than the dietary exposures that would be estimated from 
the anticipated average use levels in foods” (JECFA, 2006c). 
In the absence of more accurate information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a “modified Theoretical Added Maximum Daily Intake” 
(mTAMDI) approach based on the normal use levels reported by Industry. 
As information on use levels for the flavouring substances has not been requested by the JECFA or if 
it has not otherwise been provided to the Panel, it is not possible to estimate the daily intakes using the 
mTAMDI approach for the substances evaluated by the JECFA. The Panel will need information on 
use levels in order to finalise the evaluation. 
Threshold of 1.5 Microgram/Person/Day (Step B5) Used by the JECFA 
The JECFA uses the threshold of concern of 1.5 microgram/person/day as part of the evaluation 
procedure: 
“The Committee noted that this value was based on a risk analysis of known carcinogens which 
involved several conservative assumptions. The use of this value was supported by additional 
information on developmental toxicity, neurotoxicity and immunotoxicity. In the judgement of the 
Committee, flavouring substances for which insufficient data are available for them to be evaluated 
using earlier steps in the Procedure, but for which the intake would not exceed 1.5 microgram per 
person per day would not be expected to present a safety concern. The Committee recommended that 
the Procedure for the Safety Evaluation of Flavouring Agents used at the forty-sixth meeting be 
amended to include the last step on the right-hand side of the original procedure (“Do the condition of 
use result in an intake greater than 1.5 microgram per day?”)” (JECFA, 1999b).  
In line with the Opinion expressed by the Scientific Committee on Food (SCF, 1999), the Panel does 
not make use of this threshold of 1.5 microgram per person per day. 
Genotoxicity 
As reflected in the Opinion of SCF (SCF, 1999a), the Panel has in its evaluation focussed on a 
possible genotoxic potential of the flavouring substances or of structurally related substances. 
Generally, substances for which the Panel has concluded that there is an indication of genotoxic 
potential in vitro, will not be evaluated using the EFSA Procedure until further genotoxicity data are 
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provided. Substances for which a genotoxic potential in vivo has been concluded, will not be evaluated 
through the Procedure. 
Specifications 
Regarding specifications, the evaluation by the Panel could lead to a different opinion than that of the 
JECFA, since the Panel requests information on e.g. isomerism. 
Structural Relationship  
In the consideration of the JECFA evaluated substances, the Panel will examine the structural 
relationship and metabolism features of the substances within the flavouring group and compare this 
with the corresponding FGE. 
HISTORY OF THE EVALUATION OF THE SUBSTANCES IN THE PRESENT FGE 
The Flavouring Group Evaluation 66 concerned furfuryl alcohol and 13 related substances evaluated 
by the JECFA at their 55th meeting. Eight of the 14 substances are alpha,beta-unsaturated aldehydes or 
precursors for such, which the Panel considers to be a structural alert for genotoxicity. Accordingly, 
these eight substances were initially considered with respect to genotoxicity (see Section 1.1.2). The 
Panel concluded in FGE.218 (EFSA, 2009s) that the alpha,beta-unsaturated structure did not give rise 
to concern for genotoxicity in these eight substances, but for one of the substances, 5-methylfurfural 
[FL-no: 13.001], a genotoxicity concern could not be ruled out due to other structural alerts in the 
substance.  
 
FGE Opinion adopted 
by EFSA 
Link No. of 
candidate 
substances 
FGE.66 9 July 2008 http://www.efsa.europa.eu/EFSA/efsa_locale-
1178620753812_1211902338972.htm
14 
FGE.66Rev1 6 July 2011  14 
 
Additional genotoxicity data have become available for a structurally related substance to 5-
methylfurfural [FL-no: 13.001], namely 5-hydroxymethylfurfural [FL-no: 13.139] for which 
additional genotoxicity data have been requested in FGE.13. It is anticipated that 5-methylfurfural can 
be oxidised to the primary alcohol 5-hydroxymethylfurfural (EFSA, 2010ak) and accordingly the new 
data submitted for 5-hydroxymethylfurfural was used in FGE.218Rev1 (EFSA, 2010ak) and will be 
used in this FGE to support the evaluation of 5-methylfurfural. Therefore the evaluation of these 
genotoxicity data submitted by the Industry are included in FGE.66Rev1. 
Since the publication of FGE.66, the EU production volumes have been provided for three substances 
[FL-no: 13.003, 13.005 and 13.025], the evaluation of which could not be finalised in the previous 
version of this FGE, due to lack of these data. Based on the newly submitted EU production volumes 
these substances have already been evaluated in FGE.96, but for the sake of completion, the 
information has also been included here as well. 
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1. Presentation of the Substances in the JECFA Flavouring Group 
1.1. Description 
1.1.1. JECFA Status 
The JECFA has evaluated a group of 14 furfuryl derivatives and one benzofurancarboxaldehyde at 
their 55th meeting (JECFA, 2001a).  
1.1.2. EFSA Considerations 
Nine of the substances in the group of furfuryl alcohol and related substances evaluated by the JECFA 
(JECFA, 2001a) are alpha,beta-unsaturated aldehydes or precursors for alpha,beta-unsaturated 
aldehydes. As the alpha,beta-unsaturated aldehyde and ketone structures are considered by the Panel 
to be structural alerts for genotoxicity, these nine substances, i.e. eight substances in FGE.218 
(subgroup 4.2 of FGE.19 (EFSA, 2008b)) [FL-no: 13.001, 13.018, 13.019, 13.057, 13.062, 13.067, 
13.068 and 13.128] (EFSA, 2009s) and one substance (2-benzofurancarboxaldehyde [FL-no: 13.031]) 
from subgroup 4.3 of FGE.19 (EFSA, 2008b), have initially been considered with respect to 
genotoxicity. The Panel concluded that although the eight substances in FGE.218 (EFSA, 2009s)  and 
FGE.218Rev1 (EFSA, 2010ak) have a structural alert for genotoxicity, the data available do not 
preclude the evaluation of these eight substances through the Procedure (see Section 3.3 to 3.6). For 
the ninth substance, 2-benzofurancarboxaldehyde [FL-no: 13.031], the Panel concluded that the 
substance is structurally different from the eight substances in FGE.218 and should be considered 
separately in subgroup 4.3 from FGE.19 (EFSA, 2008b). This substance will be considered in 
Revision 1 of FGE.67, together with another structurally related flavouring substance. Accordingly the 
present FGE.66Rev1 deals with 14 of the 15 substances from the group of furfuryl alcohol and related 
substances evaluated by JECFA.  
Five [FL-no: 13.002, 13.003, 13.005, 13.025, 13.073] of the remaining six substances are esters of 
furoic acid and the sixth substance [FL-no: 13.038] is not structurally related to furfural. As for this 
substance, in other FGEs, no related compounds could be found, it will be evaluated in this FGE. 
Thus, this FGE deals with in total 14 candidate substances. Thirteen substances in the JECFA 
flavouring group of furfuryl alcohol and related substances are structurally related to the subgroup of 
10 furfuryl derivatives (without sulphur containing substituents) in the group of furfuryl and furan 
derivatives with and without additional side-chain substituents and heteroatoms evaluated by EFSA in 
FGE.13Rev2 subgroup Ia (EFSA, 2011h). The remaining substance [FL-no: 13.038] is to be evaluated 
on its own in this FGE. 
1.2. Isomers 
1.2.1. Status 
None of the JECFA evaluated substances in the group of furfuryl alcohol and related substances has a 
chiral centre or can exist as geometrical isomers. 
1.3. Specifications 
1.3.1. Status 
The JECFA specifications are available for all 14 substances (JECFA, 2000d). See Table 1. 
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1.3.2. EFSA Considerations 
Adequate specifications are available for all 14 substances.  . 
2. Intake Estimations 
2.1. Status 
For all substances evaluated through the JECFA Procedure intake data are available for the EU, see 
Table 3.1. 
2.2. EFSA Considerations 
For one of the 14 substances, [FL-no: 13.018], the Industry has submitted use levels for normal and 
maximum use (EC, 2000a; EFFA, 2000e). Based on the normal use levels an mTAMDI figure of 9700 
microgram/person/day can be calculated (EFSA, 2004d). 
Table 2.2.1  Normal and Maximum use levels (mg/kg) available for JECFA evaluated substances in 
FGE.66Rev1 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
13.018 25 
60 
- 
- 
25 
50 
 
0,25 
 
0,25 
25 
700 
5 
25 
5 
125 
- 
- 
- 
- 
- 
- 
- 
- 
25 
63 
25 
 
15 
28 
17 
30 
 
25 
 
25 
 
 
Table 2.2.2  Estimated intakes based on the MSDI approach and the mTAMDI approach 
FL-no EU Register name MSDI – EU 
(μg/capita/day) 
MSDI – USA 
(μg/capita/day) 
mTAMDI 
(μg/person/day) 
Structural 
class 
Threshold of concern 
(µg/person/day) 
13.001 5-Methylfurfural 180 25  Class II 540 
13.002 Methyl 2-furoate 30 37  Class II 540 
13.003 Propyl 2-furoate 0.061 0.1  Class II 540 
13.018 Furfural 440 460 9700 Class II 540 
13.019 Furfuryl alcohol 180 24  Class II 540 
13.057 Furfuryl isovalerate 0.024 1  Class II 540 
13.062 Furfuryl propionate 1.7 5  Class II 540 
13.068 Furfuryl valerate 0.24 14  Class II 540 
13.128 Furfuryl acetate 16 21  Class II 540 
13.005 Hexyl 2-furoate 0.061 0.1  Class III 90 
13.025 Pentyl 2-furoate 0.36 0.1  Class III 90 
13.038 2-Phenyl-3-carbethoxyfuran 0.012 2  Class III 90 
13.067 Furfuryl octanoate 0.012 6  Class III 90 
13.073 Octyl 2-furoate 2.2 0.1  Class III 90 
 
3. Genotoxicity Data 
3.1. Genotoxicity Studies – Text taken4 from the JECFA (JECFA, 2001b) 
No genotoxicity text was prepared by the JECFA on the group of furfuryl alcohol and related 
substances – the studies are only given in table format (see Table 2.1). 
                                                     
 
4 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present FGE has been removed. 
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3.2. Genotoxicity on furfural – Text taken5 from the JECFA (JECFA, 2001b) 
One of the substances in the group of furfuryl alcohol and related substances is furfural [FL-no: 
13.018], which also was considered separately at the 55th meeting (JECFA, 2001b) where the 
following was stated: 
“Furfural was evaluated previously by the Committee at its thirty-ninth and fifty-first meetings 
(JECFA, 1992a; JECFA, 2000a). An ADI was not established at either meeting because of concern 
about the finding of tumours in male mice given furfural in corn oil by gavage and the fact that no 
NOEL was identified for hepatotoxicity in male rats. In a study in mice, the combined incidence of 
adenomas and carcinomas was increased in males at the highest dose (175 mg/kg bw per day). In order 
to address its concern with regard to the formation of liver tumours in mice, the Committee at its fifty-
first meeting requested the results of studies of DNA binding or adduct formation in vivo to clarify 
whether furfural interacts with DNA in the liver of mice, and also requested the results of a 90-day 
toxicity study in rats to identify a NOEL for hepatotoxicity (JECFA, 2000a). 
Since the last meeting, the results of a 14-day study to determine a dose range, a 90-day study of 
toxicity in rats, and an assay for unscheduled DNA synthesis in mice in vivo have become available. 
These data were reviewed and are summarized in the following monograph addendum.” 
“The ability of furfural to induce DNA repair in the hepatocytes of B6C3F1 mice was assessed in an 
assay for unscheduled DNA synthesis. The maximum tolerated dose for animals of each sex was 
determined in a preliminary study to be 320 mg/kg bw. In the study of unscheduled DNA synthesis, 
doses of 50, 175, and 320 mg/kg bw were given to groups of three animals of each sex, and expression 
of DNA repair was measured 2 - 4 and 12 - 16 hours after treatment. N-Nitrosodimethylamine (20 
mg/kg bw) was used to measure expression within 2 - 4 hours and aminoazotoluene (200 mg/kg bw) 
for expression within 12 - 16 hours, as positive controls. 
The animals treated with furfural did not show increased unscheduled DNA synthesis at either time 
after dosing, whereas the positive controls showed statistically significant increases in net nuclear 
grain counts. Little replicative DNA synthesis (0 - 0.4 %) was seen at either interval. The results 
provided no evidence that furfural damages DNA in mouse hepatocytes at doses up to 320 mg/kg bw 
(Edwards, 1999).” 
“The results of an assay for unscheduled DNA synthesis in mice in vivo were reviewed by the 
Committee. This study, in which doses of up to 350 mg/kg bw were given, was particularly relevant 
since it addressed potential DNA repair in the cells in which tumours arose, namely hepatocytes. The 
negative results obtained in this assay were considered by the Committee to provide evidence that the 
liver tumours observed in the long-term study in mice were unlikely to have occurred through a 
genotoxic mechanism. The Committee considered that the concerns raised previously with respect to 
the liver tumours in mice were adequately addressed by this study and that a study of DNA binding 
was unnecessary.” 
For a summary of in vitro / in vivo genotoxicity data considered by the JECFA, see Table 2.1. 
3.3. Genotoxicity Studies – Text taken6 from FGE.13Rev2 (EFSA, 2011h) 
Data on in vitro genotoxicity were provided for the two candidate substances, 5-
hydroxymethylfurfural (5-HMF) [FL-no: 13.139] and furoic acid [FL-no: 13.136] as well as for five 
supporting substances. Data on in vivo genotoxicity were only provided on two of the supporting 
substances. New genotoxicity data on the candidate substance 5-HMF have become available and will 
be considered in this revision of FGE.13. 
                                                     
 
5 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present FGE has been removed. 
6 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present FGE has been removed. 
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Candidate substances 
5-hydroxymethyl furfural [FL-no: 13.139] 
In the in vitro tests, 5-HMF gave negative results in the traditional Ames test in strains TA98, TA100, 
TA104, TA1535 and TA1537 in five and positive results in two studies.  The validity of these two 
studies could not be assessed. In one of these two studies (Omura et al., 1983) the positive response 
was observed in strain TA100, but not in TA98 and the mutagenic potential was higher in the absence 
of S9 than in the presence of S9. In the other study (Shinohara et al., 1986) mutagenicity was only 
observed in strain TA100 in the presence of metabolic activation (See Table 2.2 of this FGE). A 
positive result was obtained also in the Umu assay, although only at high concentrations, resulting in 
reduced cell viability (Janzowski et al., 2000) and in a Rec assay on B. subtilis (Shinohara et al., 
1986). In V79 cells, 5-HMF induced a small (although statistically significant) increase in 
chromosomal aberrations, a reduction in mitotic index and, only at high concentrations, resulting in 
reduced cell viability, also HPRT mutations (Janzowski et al., 2000). In TK6 human lymphoblast 
cells, 5-HMF gave negative results in the HPRT and TK assay (Surh and Tannenbaum, 1994).  
In an Ames test with TA104 strain upon inclusion of PAPS, a sulpho-group donor, and rat liver 
cytosol into the experimental model, 5-HMF gave a positive result, suggesting that it can be activated 
to reactive metabolites following sulphation, with formation of sulphate-ester (SMF). Indeed, the 
mutagenic effect could be partly suppressed by the addition of sulphotransferase inhibitors. In 
accordance, SMF in TA104 was genotoxic in the absence of any metabolic system (cytotoxicity not 
specified); the effect was reduced by addition of glutathione (GSH) and GSH-transferases and restored 
when this latter enzyme was inhibited (Lee et al., 1995b).  
The formation of SMF was supported by the detection of an unstable conjugate, which disappeared 
within 60 minutes, when 5-HMF was incubated with 35S-PAPS and liver cytosol. The exact nature of 
SMF was not elucidated, but its molecular mass was consistent with that of the sulphate-ester of 5-
HMF (Surh and Tannenbaum, 1994). 
When the genotoxicity of chemically synthesised SMF was tested in Salmonella strain TM677 (8-AG-
resistance), without any metabolic activation, a clear positive response was obtained at concentrations 
that reduced cell survival to < 60 %. Genotoxicity was also observed with SMF in human 
lymphoblasts at the tk and hprt loci, at concentrations (> 40 microg/ml) reducing cell survival to > 63 
%. No genotoxicity was observed with 5-HMF, with its acetate ester or with the sulphation product of 
2-methyl furfuryl alcohol, suggesting that the genotoxicity of SMF requires the presence of both a 
reactive sulphate group and a free aldehyde group. 
An assay for primary DNA damage (Comet assay) did not show an effect of 5-HMF in V79 and Caco-
2 cells up to cytotoxic concentrations (80 mM). 5-HMF caused a slight but significant increase in 
DNA single strand breaks in primary rat hepatocytes at cytotoxic levels (40 - 100 mM), whereas in 
human colon biopsy material the same effect was seen in the absence of cytotoxicity. 5-HMF at non-
cytotoxic concentrations induced a substantial concentration-related GSH depletion in V79, Caco-2 
and rat liver cells. The effect of sulphate conjugation was not directly studied, but since this activity is 
present at least in primary hepatocytes, it might have contributed to the depletion of GSH and to 
induction of DNA strand breaks in these cells. However, this study was not considered appropriate to 
evaluate the possible mutagenic activity of SMF in mammalian cells and consequently of 5-HMF in 
vivo (Janzowski et al., 2000). 
To support the genotoxic potential of 5-HMF, some indications for tumorigenic activities of 5-HMF 
have been obtained with rats and mice. It has been reported that 5-HMF may act as both an initiator 
and a promoter in the induction of colonic aberrant cryptic foci in rats (Archer et al., 1992; Bruce et 
al., 1993; Zang et al., 1993). In addition, induction of skin papillomas has been described after topical 
application of doses of 10 or 25 micromol 5-HMF to mice (Surh et al., 1994). 
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“Newly submitted data on 5-hydroxymethylfurfural7 
Weak mutagenic activity was reported in S. typhimurium TA100 strain in the absence of metabolic 
activation, while no mutagenicity was observed in strains TA97, TA98, TA102 and TA1535 in a range 
of concentrations of 100 - 10,000 micrograms/plate; however, negative results were reported in 
another study with TA98 and TA100 strains and E. coli WP2 uvrA/pKM101 in a range of 
concentrations of 1,500 - 10,000 micrograms/plate (NTP, 2010c). 
At the end of a 3-month toxicity study, peripheral blood samples were obtained from male and female 
B6C3F1 mice receiving 0, 47, 188, 375 or 750 mg/kg bw/day of 5-HMF via gavage. Slides were 
scanned to determine the frequency of micronuclei in 1,000 normochromatic erythrocytes (NCEs) in 
10 animals per sex per treatment group. In addition, the percentage of polychromatic erythrocytes 
(PCE) in a population of 1,000 erythrocytes was determined as a measure of bone marrow toxicity. No 
increases in the frequency of micronucleated erythrocytes were observed; in addition, no significant 
dose-related changes in the percentage of immature PCE were observed, suggesting that the chemical 
did not exhibit bone marrow toxicity (NTP, 2010c). 
The DNA-damaging potential of 5-HMF was tested in vitro in the Comet assay with the following five 
cell lines with various degree of SULT1A1 expression (Durling et al., 2009): two human lines (Caco-
2, no detectable 1A1 activity; HEK293, high 1A1 activity); two cell lines from Chinese hamster (V79, 
no detectable 1A1 activity and V79-hp-PST, high 1A1 activity) and a one mouse lymphoma line 
(L5178Y, no detectable activity). The cell lines were incubated with 0, 2.5, 7.5, 25, 50 or 100 mM (ca. 
0, 0.3, 1.0, 3.3 6.3 or 12.6 mg/ml) of 5-HMF for three hours and subjected to a Comet assay to study 
DNA damage. 
DNA damage was observed at the highest concentration (100 mM) in all cell lines, with significant 
reduction in cell viability (from 11 to 30 %), The concentration of 100 mM is ten times higher than the 
highest concentration (10 mM or 5000 micrograms/ml) recommended by OECD guidelines for in vitro 
testing with mammalian cells. 100 mM was the lowest effective concentration for three cell lines: 
Caco-2, HEK293 and L5178Y. In the V79 (lowest SULT1A1) and V79-hp-PST (highest SULT1A1) 
DNA damage was induced also at lower concentrations (lowest effective concentration: 25 mM or 
3193 micrograms/ml), without a reduction in cell viability. Surprisingly, the positive control (HMP, 
0.01 mM) induced significant damage in Caco-2, V79 and V79-hp-PST cells, but not in HEK293. The 
authors (Durling et al., 2009) concluded that DNA damage induced in all cell lines was unrelated to 
the expression of SULT1A1 but they mentioned that the SULT1A1 activities in these three cell lines 
(Caco-2, HEK293 and L5178Y) were much lower than those that can be found in human gut and liver. 
The possibility was left open that SULT1A1 activity was too low to efficiently bioactivate 5-HMF 
also in the cell line with highest SULT1A1 activity. In V79 cells without SULT1A1 activity and in 
V79-hp-PST with SULT1A1 activity at the same level as in human gut and liver, no difference in 
extent of DNA-damage could be observed. This would indicate absence of a significant contribution 
of sulphate conjugation in the DNA-damaging activity of 5-HMF.  
These results are in conflict with the results of Glatt et al. (Glatt et al., 2005) who reported induction of 
SCE in 5-HMF-exposed genetically modified V79 cells expressing high levels of human CYP2E1 and 
SULT1A1. They are also in conflict with the observations by Sommer et al. (Sommer et al., 2003) 
reporting the mutagenicity of 5-HMF in a S. typhimurium strain genetically modified and expressing 
human SULT1A1. According to Durling et al. (2009), the reasons of these discrepancies are unknown; 
one possibility is the different sensitivity of the COMET assay compared to other systems. Durling et 
al. (Durling et al., 2009) concluded that other important mechanisms for the observed DNA damage 
                                                     
 
7 An in vivo micronucleus test in mouse bone marrow with neofuraneol was also submitted, but an adequate identification of 
the substance studied was not possible due to incomplete reporting. The study did not show an effect of neofuraneol on the 
occurrence of micronuclei. Since no target organ toxicity was seen, this evidence provided by this study is of very limited 
relevance. For these two reasons the study is not further discussed. 
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should be investigated, but that under the conditions of the test, 5-HMF is a rather weak DNA-
damaging agent. 
In a new publication by Severin et al. (2010), a dose dependent increase in DNA damage was 
observed in an COMET assay with HepG2 cells exposed to 5-HMF (0, 5.35, 7.87, 11.57, 17, 25, 36.6 
mM) for 20 hours, with a significant increase from 7.87 to 36.6 mM 5-HMF. Cytotoxicity was 
observed at the two highest doses (25 and 36.6 mM), with estimated IC50 of 38 mM. HepG2 cells 
express both CYP and SULT enzymes. In the same publication no effect of 5-HMF was found in an in 
vitro micronucleous assay in the same cell line exposed to similar doses of HMF (20 hours). HMF was 
also tested in an Ames test performed according to the OECD guidelines 471. No increase in mutants 
was observed in S. typhimurium strains TA 98, TA 100, TA1535 and TA 1537 exposed to 5-HMF at 
0.5 µg/mL up to 5000 µg/mL with or without metabolic activation (S9). However, no additional PAPS 
was added to the test system (Severin et al., 2010).  
However, while 5-HMF was unable to induce micronuclei in vivo, in the NTP 3-months study in mice 
by gavage, and in vitro, using the Hep-G2 human cell line expressing both CYP and SULT enzymes, 
its metabolite SMF has been reported to induce micronuclei in peripheral erythrocytes in mice 
((Dahlberg, 2004) as cited by Glatt and Sommer, 2006 (no further data were available)). 
According to Glatt and Sommer, incubation of DNA with SMF in a cell-free system led to the 
formation of DNA adducts that could be detected by the 32P-postlabelling technique. No adducts were 
formed in incubations with 5-HMF instead of SMF. In subsequent experiments, the authors searched 
for these adducts in mammalian and bacterial cells treated with SMF and in SULT-proficient cells 
treated with 5-HMF. Although mutations were induced, adducts were not seen in these cells under the 
same conditions. The authors hypothesized that the lack of DNA adducts might be due to technical 
problems, since generally DNA adducts are a more sensitive endpoint than mutations as observed with 
many other compounds (Glatt and Sommer, 2006). 
In conclusion, with respect to the genotoxicity 5-HMF, taking into account additional data on 
metabolism, the following picture emerges. The substance is negative in the conventional Ames test. 
Mutagenicity is observed only upon inclusion of PAPS, a sulpho-group donor and liver cytosol into 
the metabolic system, suggesting the formation of a sulphate-ester (SMF). In accordance, SMF was 
mutagenic in the absence of any metabolic activation system. In an in vitro assay, 5-HMF induced 
dose-dependent increase in DNA damage (Comet assay), but this study has major drawbacks and 
inconsistencies and has to be considered of limited validity. A major limit is the use of too high 
concentrations that can produce unpredictable effects, not related to the real genotoxic potential  of 5-
HMF, and this is particularly true for a test like the Comet assay. Furthermore, as also stated by the 
authors, DNA damage was unrelated to the expression of SULT1A1 activity. Also in another Comet 
assay in HepG2 cells, able to express both CYP and SULT enzymes, indications for DNA damage 
were observed, but the substance did not induce clastogenic or aneugenic effects (micronucleus assay) 
in the same cell system. In vivo, a non-standard micronucleus assay in peripheral blood erythrocytes 
associated to a sub-chronic study in mice, provided no indication of a genotoxic potential, but this 
study has limited validity since no bone marrow cell toxicity was observed. 
Metabolic studies indicate that in vivo, in mice B6C3F1 and rats, the principal route of metabolism is 
oxidation of 5-HFM to 5-hydroxymethylfuroic acid, followed by glycine conjugation and rapid 
elimination in the urine. However, a recent pharmacokinetic study in FVB/N mice has shown that 
SMF has been detected in plasma from animals given 5-HMF, intravenously. This indicates that there 
is a competition for the substrate 5-HMF between the oxidation pathway leading to the furoic acid 
derivative and the sulphonation pathway leading to the SMF metabolite. The Panel noted that SMF is 
very hydrophilic and therefore will have problems crossing the cell membrane and entering cells. 
Therefore SMF is more likely to induce mutation at the site of formation, mainly the liver. In addition, 
the half life was reported to be 4.2 minutes, and it is not likely that this metabolite will manage to 
reach the bone marrow and give any positive effect in an in vivo micronucleous test, taking into 
account that SMF will most likely be formed in the liver. However, 5-HMF has been found unable to 
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induce micronuclei also in vitro, using the HepG2 human cell line, expressing both CYP and SULT 
enzymes. In the rodents bioassays no carcinogenic response was observed and from this it may be 
concluded that the formation of the SMF metabolite is too low to result in a carcinogenic response. 
Assuming that in humans the ratio between the two competing pathways is not more favourable for the 
formation of SMF than in rodents, no gentoxicity or carcinogenicity is expected in humans either.” 
Furoic acid [FL-no: 13.136] 
Furoic acid gave negative results in three studies in the Ames test in strains TA98 and TA100. Furoic 
acid was also negative in DNA repair test in E. coli and in an UDS assay using primary rat 
hepatocytes. 
Supporting substances 
In vitro genotoxicity data were available for five supporting substances (furfuryl acetate, furfuryl 
alcohol, furfural, 5-methylfurfural and methyl-2-furoate) and in vivo genotoxicity data for the two 
supporting substances furfuryl alcohol and furfural. Most studies were negative, although some 
positive results were reported. However, the genotoxicity of furfural has recently been re-evaluated by 
the AFC Panel, which concluded that furfural did not induce gene mutations in vivo, on the basis of 
new studies with transgenic mice (EFSA, 2004c).  
Overall, the genotoxicity data available on the candidate furoic acid and on the supporting substances 
do not give rise to concern with respect to genotoxicity of nine candidate furfural-related candidate 
substances included in subgroup Ia [FL-no: 13.011, 13.102, 13.122, 13.127, 13.129, 13.130, 13.132, 
13.133 and 13.136]. Based on newly submitted data on the mutagenic activity of 5-HMF [FL-no: 
13.139] the concern for genotoxicity which was raised because of genotoxic properties of one of its 
metabolites (SMF) is overcome. Thus there are no further concerns for genotoxicity of the candidate 
substances in subgroup Ia of FGE.13Rev2, which could preclude their evaluation through the 
Procedure. 
For a summary of in vitro / in vivo genotoxicity data considered by EFSA, see Table 2.2 and 2.3. 
3.4. SCF Opinion on Furfural and Furfural Diethylacetal8 (SCF, 2003a) 
“Special studies on genotoxicity 
Negative or weakly positive results have been obtained for most bacterial tests for genotoxicity. In 
particular, positive results were obtained in three out of several assays for reverse mutation in S. 
typhimurium at relatively high concentrations in the absence of metabolic activation. Furfural was 
found to be clearly genotoxic in cultured mammalian cells at the gene and chromosome level in the 
absence of metabolic activation. It induced SCE in cultured CHO cells and human lymphocytes. It was 
genotoxic in Drosophila in somatic cells (Wing spot test by inhalation) and germ cells (sex-
chromosome loss by injection). It did not induce reciprocal translocations and sex-linked recessive 
lethal mutations, with only a doubtful increase in one study in Drosophila. Furfural was not genotoxic 
in any in vivo mammalian assays for chromosome aberrations, SCE or UDS.”  
Conclusion 
“The Committee was of the opinion that the data were not totally convincing in demonstrating that the 
carcinogenicity of furfural was mediated via a thresholded mechanism and hence was unable to 
allocate an ADI to furfural at the present time. It was aware that a study in transgenic mice of the 
potential of furfural to induce gene mutations in vivo was in progress. The results were expected to be 
                                                     
 
8 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present FGE has been removed. 
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available in the near future and the Committee would wish to re-evaluate furfural in the light of the 
results of this study.” 
The results of genotoxicity studies on furfural are summarised in Table 2.4. 
3.5. EFSA Opinion on Furfural and Furfural Diethylacetal9 (EFSA, 2004c) 
“Special Studies on Genotoxicity 
In a new study not previously evaluated by the SCF, furfural was examined for its potential to induce 
gene mutations of the λlacZ-gene in vivo in the liver of male transgenic mice (CD2F1(BALB/c x 
DBA/2) strain 40.6, with lacZ-genes as reporter genes). The study was carried out under GLP. As 
formal technical guidelines for this type of study are not available, the study protocol was designed in 
conformity with principles for transgenic studies identified by international expert groups (Gorelick 
and Mirsalis, 1996; Heddle et al., 2000). The study was conducted in five groups, three of which 
received furfural by gavage in corn oil, one negative control group received vehicle alone and one 
positive control group received ethylnitrosourea (ENU). The furfural and negative control groups each 
comprised 13 mice plus 2 back up animals; the positive control group comprised 8 mice plus 2 
reserves. The furfural groups were given doses of 75, 150 or 300 mg furfural/kg bw in corn oil by 
gavage for 28 consecutive days; ENU was given to the positive control group by intraperitoneal 
injection in saline on days 5 - 9 of the study at a dose of 50 mg/kg bw/day. On day 28, three animals 
from each of the furfural and negative control groups were sacrificed for assessment of hepatotoxicity 
by clinical chemistry and histological examination. In addition, organ and body weights were 
monitored throughout. After a manifestation period of 34 - 35 days (days 62 - 63 of the study), the 
livers and samples of gastrointestinal tract tissues were fixed for mutation analysis. Mutation analysis 
was carried out on the livers of eight animals per group. At least 5000 (preferably 120,000) plaque-
forming units (PFU) were examined (one PFU corresponding to one recovered copy of the λgt10lacZ 
shuttle vector).  
There were three early decedents in the highest furfural dose group; two during treatment with no 
clinical signs, and one during the manifestation period. One animal from the low-dose group died 
during the manifestation period. The cause of death could not be ascertained.  
Body weights in the furfural-treated groups showed a dose related increase compared to negative 
controls during the first week of treatment. In the post-treatment period the difference between control 
and two lower dose groups disappeared but the body weight of the group treated with 300 mg 
furfural/kg bw remained higher.  
Evaluation of the clinical chemistry and gross and histopathology of the liver of the treated animals 
sacrificed at the end of the treatment period showed an increase in blood triglycerides, increased liver 
weight and centrilobular hypertrophy. This was interpreted by the authors as some evidence of 
hepatotoxicity. These changes did not persist until the end of the manifestation period, 34 - 35 days 
after the last dose.  
The mutation frequency in DNA extracted from the livers of the negative control group was similar to 
historical data. There was no significant difference in mutation frequency between negative controls 
and the furfural-treated groups; the positive control group showed a significant increase in mutation 
frequency. It was concluded that oral administration of furfural in corn oil at levels of up to 300 mg/kg 
bw/day is not associated with an increase in the induction of mutations in liver cells of λlacZ 
transgenic mice (CIVO-TNO, 2003).  
                                                     
 
9 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present FGE has been removed. 
Flavouring Group Evaluation 66, Revision 1
 
 
15 EFSA Journal 2011; 9(9):2314 
Negative or weakly positive results have been obtained for most bacterial tests for genotoxicity. In 
particular, positive results were obtained in three out of several assays for reverse mutation in 
Salmonella typhimurium at relatively high concentrations in the absence of metabolic activation. 
Furfural was found to be clearly genotoxic in cultured mammalian cells at the gene and chromosome 
level in the absence of metabolic activation. It induced Sister Chromatid Exchange (SCE) in cultured 
Chinese Hamster Ovary (CHO) cells and human lymphocytes. It was genotoxic in Drosophila in 
somatic cells (Wing spot test by inhalation) and germ cells (sex-chromosome loss by injection). It did 
not induce reciprocal translocations and sex-linked recessive lethal mutations, with only a doubtful 
increase in one study in Drosophila. Furfural was not genotoxic in any in vivo mammalian assays for 
chromosome aberrations, SCE or Unscheduled DNA Synthesis (UDS) and the study in transgenic 
mice confirms that furfural does not induce gene mutations in vivo. 
Discussion 
The Panel noted the metabolic and toxicity data previously reviewed by the SCF together with the new 
results of the genotoxicity study in transgenic mice in vivo.  
Furfural was negative in the in vivo genotoxicity assay and this corroborated earlier negative in vivo 
studies at the chromosome level and in a UDS assay.  
In view of the absence of genotoxicity in vivo, the tumours observed in the long-term 
toxicity/carcinogenicity studies in male, but not female mice, are considered to arise as a consequence 
of chronic hepatotoxicity (hepatocellular necrosis) which was more marked in male animals. An 
increased tumour incidence was only observed at the highest dose level and at a dose higher than the 
minimal hepatotoxic dose.  
It should be noted that no hepatocellular tumours were seen in the long-term rat study. However, liver 
toxicity was seen in this study (see SCF Opinion, Appendix 1) and the rat was considered more 
sensitive to liver toxicity.  
The hepatotoxicity of furfural is dose-dependent but a NOEL was not established in the long-term 
studies. However, the short-term (90-day) study in rats was conducted to establish a NOEL for 
hepatotoxicity, which was determined to be 54 mg/kg bw. The Panel noted that because of possible 
formulation (corn oil) and dose regimen (bolus dose) effects observed in the gavage studies, the 
dietary administration studies were more appropriate for identifying a NOAEL. The Panel concluded 
that the NOAEL of 54 mg/kg bw/day for hepatic changes from the 90 day dietary study was 
appropriate and noted that the effects observed with doses up to threefold higher were of doubtful 
toxicological relevance. Therefore the Panel concluded that a safety factor of 100 would be sufficient 
in establishing an ADI from this subchronic study (see SCF Opinion). 
Conclusion and Recommendation 
The Panel concluded that furfural did not exhibit genotoxicity in vivo in male mice, the species and 
sex which displayed an increased tumour incidence in long-term studies and that the tumours arose by 
a secondary mechanism consequent on hepatotoxicity, which is dose dependent, displays a threshold 
and is seen in both rats and mice. It was therefore considered that the NOEL for hepatotoxicity in the 
rat could be used to derive an ADI for furfural.  
An ADI for furfural was established at 0.5 mg/kg bw based on the NOEL of 54 mg/kg bw from the 
90-day rat study to which a 100-fold safety factor was applied. Since furfural diethylacetal is rapidly 
converted to furfural at physiological pH, the ADI applies also to the furfural component of furfural 
diethylacetal since furfural is readily liberated from the acetal in vivo.” 
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3.6. EFSA Considerations 
In the evaluation of the genotoxic potential of the substances in FGE.218 (EFSA, 2009s), the Panel 
has taken into consideration the SCF Opinion expressed in December 2002 on furfural and furfural 
diethylacetal (SCF, 2003a) (See Section 3.4). This Opinion was later updated by EFSA in June 2004 
(EFSA, 2004c) with consideration of additional data on the potential genotoxicity of furfural (See 
Section 3.5). Furthermore the evaluation by the JECFA on furfural and furfuryl alcohol and related 
flavouring agents at its 55th meeting (JECFA, 2001b) has been considered by the Panel (See Section 
3.1 and 3.2). 
The Panel concluded that the data available on seven of the eight substances in FGE.218 [FL-no: 
13.018, 13.019, 13.057, 13.062, 13.067, 13.068 and 13.128] do not preclude the evaluation of these 
substances through the Procedure. Therefore, they can be evaluated together with the other six 
substances [FL-no: 13.002, 13.003, 13.005, 13.025, 13.038 and 13.073] from the JECFA group of 
furfuryl alcohol and related substances (JECFA, 2001b). 5-Methylfurfural [FL-no: 13.001] can be 
oxidised in the 5-methyl-group of the hetero-aromatic system to form 5-hydroxymethylfurfuraldehyde 
[FL-no: 13.139]. In FGE.13 (EFSA, 2005c), it was concluded that 5-hydroxymethylfurfuraldehyde 
may be metabolised to 5-[(sulphoxy)methyl]furfural, which shows genotoxic potential in vitro and that 
the Procedure could not be applied for this substance. However, after the publication of FGE.13 
sufficient data have been provided to mitigate this concern with respect to genotoxic potential of [FL-
no: 13.139] in vivo (EFSA, 2011h) and accordingly there is no concern for 5-methylfurfural [FL-no: 
13.001], as concluded in FGE.218Rev1(EFSA, 2010ak). So, the Panel agrees with JECFA that [FL-
no: 13.001] may also be evaluated using the Procedure. 
4. Application of the Procedure 
4.1. Application of the Procedure to Furfuryl Alcohol and Related Substances, Text taken 
from the JECFA (JECFA, 2001b) 
Step 1 
In applying the Procedure for the safety evaluation of flavouring substances, the JECFA assigned nine 
of the 14 substances in this consideration [FL-no: 13.001, 13.002, 13.003, 13.018, 13.019, 13.057, 
13.062, 13.068 and 13.128] to structural class II (Cramer et al., 1978). Furfuryl propionate [FL-no: 
13.062] was assigned to this class because it is structurally closely related to furfuryl acetate [FL-no: 
13.128] and furfuryl pentanoate [FL-no: 13.068]. The remaining five substances [FL-no: 13.005, 
13.025, 13.038, 13.067 and 13.073] were assigned to structural class III. 
Step 2 
The data on the metabolism of individual members of the group were sufficient to draw conclusions 
about their probable metabolic fate. Most substances ([FL-no: 13.002, 13.003, 13.005, 13.018, 13.019, 
13.025, 13.057, 13.062, 13.067, 13.068, 13.073 and 13.128]) are predicted to be metabolised to 2-
furoic acid or a 2-furoic acid derivative, which is either conjugated with glycine and excreted in the 
urine or condensed with acetyl CoA and conjugated with glycine before excretion in the urine. 
Because of concern about the results of the toxicological studies on furfural in rodents, these 
substances cannot be predicted to be metabolised to innocuous products. The evaluation of all 
substances in this group therefore proceeded via the B-side of the scheme. 
Step 3 
The estimated daily per capita intakes of all 14 substances in this group are below the threshold of 
concern for the respective structural classes (i.e. 540 µg/day for structural class II and 90 µg/day for 
structural class III). Accordingly, the evaluation of all 14 substances in the group proceeded to step 
B4. 
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Step 4 
For furfural, the NOEL of 53 mg/kg bw/day in a 13-week feeding study in rats (Jonker, 2000b) 
provides an adequate margin of safety (> 1000 times) in relation to the known levels of intake of this 
substance. This NOEL is also appropriate for furfuryl alcohol [FL-no: 13.019] and the structurally 
related substances furfuryl acetate [FL-no: 13.128], furfuryl propionate [FL-no: 13.062], furfuryl 
pentanoate [FL-no: 13.068], furfuryl octanoate [FL-no: 13.067] and furfuryl 3-methylbutanoate [FL-
no: 13.057], because all of these esters would be hydrolysed to furfuryl alcohol [FL-no: 13.019] and 
then oxidised to furfural [FL-no: 13.018]. The NOEL for furfural is also appropriate for the esters of 
furoic acid, methyl 2-furoate [FL-no: 13.002], propyl 2-furoate [FL-no: 13.003], amyl 2-furoate [FL-
no: 13.025], hexyl 2-furoate [FL-no: 13.005] and octyl 2-furoate [FL-no: 13.073], which would be 
hydrolysed to furoic acid, the major metabolite of furfural. The NOEL for furfural is also appropriate 
for 5-methylfurfural [FL-no: 13.001], which would participate in the same metabolic pathways and 
also undergo alkyl oxidation. For 2-phenyl-3-carbethoxyfuran [FL-no: 13.038], the NOEL of 13 
mg/kg bw/day in a 90-day feeding study in rats (Posternak et al., 1969) provides an adequate margin 
of safety (> 1000 times) in relation to the known levels of intake of this substance. 
The evaluation of the 14 substances are summarised in Table 3.1: Summary of Safety Evaluation of 
Furfuryl Derivatives (JECFA, 2001b). 
4.2. Application of the Procedure to a Group of Furfuryl and Furan Derivatives with and 
without Additional Side-Chain Substituents and Heteroatoms Evaluated by EFSA, 
Text taken from FGE.13Rev2 (EFSA, 2011h) 
Only text relevant for substances in FGE.66Rev1 has been cited from the Procedure in FGE.13Rev2 
One of the 10 candidate substances, 5-hydroxymethylfurfuraldehyde [FL-no: 13.139], may be 
metabolised to 5-[(sulphoxy)methyl]furfural, which shows genotoxic potential in vitro. Sufficient data 
have been provided to mitigate this concern with respect to genotoxic potential in vivo. 
For the safety evaluation of the 10 candidate substances from subgroup Ia of FGE.13Rev2 the 
Procedure as outlined in Annex I was applied. The stepwise evaluations of the 10 substances are 
summarised in Table 3.2. 
Step 1 
According to the decision tree approach by Cramer et al. (Cramer et al., 1978) four candidate 
substances are classified into structural class II [FL-no: 13.122, 13.130, 13.136 and 13.139] and six 
substances are classified into structural class III [FL-no: 13.011, 13.102, 13.127, 13.129, 13.132 and 
13.133]. 
Step 2 
None of the candidate substances is predicted to be metabolised to innocuous products. Therefore, the 
evaluation of the 10 candidate substances proceeds via the B-side of the evaluation scheme. 
Step B3 
Four candidate substances, have been assigned to structural class II, and have estimated European 
daily per capita intakes (MSDI) ranging from 0.013 to 0.39 microgram (Table 3.2). These intakes are 
below the threshold of concern of 540 microgram/person/day for structural class II. Six candidate 
substances have been assigned to structural class III, and have estimated European daily per capita 
intakes (MSDI) ranging from 0.11 to 0.89 microgram (Table 3.2). These intakes are below the 
threshold of concern of 90 microgram/person/day for structural class III. Therefore, the safety 
evaluation proceeds to step B4 for all 10 candidate substances. 
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Step B4 
Considering that the 10 candidate substances are metabolised to yield furfural and furoic acid or 
furanecrylic acid, the toxicity of the esters of furfuryl alcohol [FL-no: 13.127, 13.129, 13.130, 13.132, 
and 13.133], furoic acid [FL-no: 13.102 and 13.122] and furanacrylic acid [FL-no: 13.011] is expected 
to be similar to that of the structurally related supporting substance furfural [FL-no:13.018] and of the 
candidate substance 2-furoic acid [FL-no: 13.136], which is the major metabolite of furfural. For 
furfural [FL-no: 13.018] an ADI value of 0.5 mg/kg bw has recently been established by EFSA 
(EFSA, 2004c). The estimated daily per capita intakes based on the MSDI approach expressed in 
microgram/kg body weight (bw)/day of candidate substances in subgroup Ia of the present 
FGE.13Rev2 are more than 30.000 fold below the ADI value. 
For 5-HMF [FL-no: 13.139] a substantial amount of substance-specific data are available, including 
13-week subchronic studies and chronic studies in B6C3F1 mice and F344/N rats (NTP, 2010c). The 
carcinogenicity study in mice demonstrated that 5-HMF may induce liver tumours, but these are 
considered irrelevant for humans. In contrast, no carcinogenic responses have been reported in the 
study with rats. The data have shown that the critical effect is cytoplasmic alterations in renal proximal 
tubule epithelium in mice, observed in the 13-weeks study with mice at 188 mg/kg bw/day for 5 
days/week and above with an intermittent dose regimen of five days per week. For this effects a 
Benchmark Dose, Lower Confidence Limit (BMDL) of 20.2 mg/kg bw for 5 days/week can be 
derived, which would be equivalent to 14.4 mg/kg bw/day, when corrected for continuous daily 
administration. When this BMDL of 14.4 mg/kg bw/day derived from the 13-weeks study in mice is 
compared to the MSDI of 0.39 microgram/capita/day for this substance, a margin of safety of 2.2 × 
106 can be calculated. From this it is concluded that 5-HMF [FL-no: 13.139] does not raise a safety 
concern as a flavouring substance, at its current level of use in foods. 
In summary, it can be concluded at step B4 of the Procedure that the 10 candidate substances included 
in FGE.13Rev2 pose no safety concern when they are used as flavouring substances at the estimated 
levels of daily per capita intake based on the MSDI approach. 
The stepwise evaluations of the 10 substances are summarised in Table 3.2: Summary of Safety 
Evaluation Applying the Procedure (EFSA / FGE.13Rev2) 
4.3. EFSA Considerations 
The Panel agrees with the application of the Procedure as performed by the JECFA for 13 of the 14 
substances in the group of furfuryl alcohol and related substances considered in this FGE. For 5-
methylfurfural [FL-no: 13.001] it is anticipated that the 5-methylgroup can be oxidised to the primary 
alcohol 5-hydroxymethylfurfural [FL-no: 13.139]. In FGE.13 it was concluded that 5-
hydroxymethylfurfural may be metabolised to 5-[(sulphoxy)methyl]furfural, which shows genotoxic 
potential in vitro and could therefore not be evaluated through the Procedure (EFSA, 2005c). 
However, after the publication of FGE.13, sufficient data have been provided to mitigate this concern 
with respect to genotoxic potential in vivo (EFSA, 2011h), and the Panel can agree to evaluate [FL-no: 
13.001] according to the Procedure. The Panel concluded it more appropriate to evaluate the exposure 
estimate of 180 microgram/capita/day (MSDI) for 5-methylfurfural [FL-no: 13.001] against the 
BMDL of 14.4 mg/kg bw/day derived in FGE.13Rev2 for 5-hydroxymethylfurfural [FL-no: 13.139]. 
For 5-methylfurfural an adequate Margin of Safety of 4800 can be calculated. So, the Panel can agree 
in the outcome of the Procedure as performed by the JECFA for [FL-no: 13.001] as well. 
In the previous version of FGE.66, for three substances [FL-no: 13.003, 13.005 and 13.025] no 
European production figures were available and no MSDI could be calculated at the time where 
FGE.66 was published. Consequently the safety in use could not be assessed using the Procedure 
based on the MSDI approach for these three substances. Since the publication of FGE.66, the EU 
production volumes have been provided for these three substances. For all three substances [FL-no: 
13.003, 13.005 and 13.025], which were evaluated via the B-side of the Procedure, an adequate 
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margin of safety could be calculated using the NOAEL for the structurally related furfural [FL-no: 
13.018]. Therefore the Panel concluded at step B4 that these substances would be of no safety concern 
at their estimated levels of intake based on the MSDI approach (EFSA, 2010aj). 
5. Conclusion 
The JECFA has evaluated 15 furfuryl alcohol derivatives at their 55th meeting. The Panel concluded 
that 14 substances in FGE.66 are structurally related to the subgroup of 10 furfuryl derivatives in the 
group of furfuryl and furan derivatives with and without additional side-chain substituents and 
heteroatoms evaluated by EFSA in FGE.13Rev2. The 15th substance [FL-no: 13.031] is considered too 
structurally different from the other 14 to be included in the present FGE. This substance will be 
evaluated in FGE.67. 
Eight of the candidate substances in this FGE are alpha,beta-unsaturated aldehydes or precursors for 
such which is a structural alert for genotoxicity. These eight substances [FL-no: 13.001, 13.018, 
13.019, 13.057, 13.062, 13.067, 13.068 and 13.128] have initially been considered with respect to 
genotoxicity. The Panel concluded that for all eight substances, the genotoxicity data available do not 
preclude their evaluation through the Procedure. No concern for genotoxicity was identified for the 
remaining six substances without the alpha,beta structural alert [FL-no: 13.002, 13.003, 13.005, 
13.025, 13.038 and 13.073].  
The Panel agrees with the application of the Procedure as performed by the JECFA for 13 substances 
considered in this FGE [FL-no: 13.002, 13.003, 13.005, 13.018, 13.019, 13.025, 13.038, 13.057, 
13.062, 13.067, 13.068, 13.073 and 13.128]. In contrast to the JECFA, the Panel evaluated the 
fourteenth substance [FL-no: 13.001] by comparison with a BMDL for a metabolite (5-
hydroxymethylfurfural; [FL-no: 13.139]). For none of the candidate substances in this FGE a safety 
concern was identified. 
For 13 substances [FL-no: 13.001, 13.002, 13.003, 13.005, 13.019, 13.025, 13.038, 13.057, 13.062, 
13.067, 13.068, 13.073 and 13.128] use levels are needed to calculate the mTAMDIs in order to 
identify those flavouring substances that need more refined exposure assessment and to finalise the 
evaluation. For one substance, furfural [FL-no: 13.018] use levels have been provided by Industry and 
an mTAMDI figure of 9700 microgram/person/day could be calculated. 
In order to determine whether the conclusion for the substances considered in this FGE can be applied 
to the materials of commerce, it is necessary to consider the available specifications. Adequate 
specifications including purity criteria and identity test are available for all 14 JECFA evaluated 
substances considered in the present FGE. 
Thus, for all 14 JECFA evaluated furfuryl derivatives [FL-no: 13.001, 13.002, 13.003, 13.005, 13.018, 
13.019, 13.025, 13.038, 13.057, 13.062, 13.067, 13.068, 13.073 and 13.128] the Panel agrees with the 
JECFA conclusion “No safety concern at estimated levels of intake as flavouring substances” based on 
the MSDI approach. 
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TABLE 1: SPECIFICATION SUMMARY  
Table 1: Specification Summary of the Substances in the Group of furfuryl alcohol and related flavouring substances evaluated by the JECFA (JECFA, 2000d) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
13.001 
745 
5-Methylfurfural O
O
 
2702 
119 
620-02-0 
Liquid 
C6H6O2 
110.11 
Slightly soluble 
Miscible 
187 
 
IR 
97 % 
1.525-1.532 
1.098-1.108 
13.002 
746 
Methyl 2-furoate 
O
O
O
 
2703 
358 
611-13-2 
Liquid 
C6H6O3 
126.11 
Insoluble to slightly soluble 
Miscible 
181 
 
IR 
98 % 
1.485-1.490 
1.176-1.181 
13.003 
747 
Propyl 2-furoate O
O
O
 
2946 
359 
615-10-1 
Liquid 
C8H10O3 
154.17 
Slightly soluble 
Miscible 
211 
 
MS 
97 % 
1.471-1.475 
1.067-1.075 
13.005 
749 
Hexyl 2-furoate O
O
O
 
2571 
361 
39251-86-0 
Liquid 
C11H16O3 
196.25 
Insoluble 
Miscible 
252 
 
IR 
97 % 
1.468-1.473 
1.015-1.020 
13.018 
450 
Furfural O
O
 
2489 
2014 
98-01-1 
Liquid 
C5H4O2 
96.10 
soluble 
miscible  
161-162 
 
IR 
95 % 
1.521-1.529 
1.153-1.162 
13.019 
451 
Furfuryl alcohol O
OH
 
2491 
2023 
98-00-0 
Liquid 
C5H6O2 
98.1 
miscible 
miscible 
169-171 
 
IR 
97 % 
1.481-1.489 
1.126-1.136 
13.025 
748 
Pentyl 2-furoate O
O
O
 
2072 
2109 
1334-82-3 
Liquid 
C10H14O3 
182.22 
Insoluble 
Miscible 
95-97 (1.3 hPa) 
 
IR 
98 % 
1.469-1.475 
1.031-1.038 
13.038 
752 
2-Phenyl-3-carbethoxyfuran 
O
O
O
3468 
2309 
50626-02-3 
Liquid 
C13H12O3 
216.24 
Slightly soluble 
Miscible  
148-154 (8 hPa) 
 
IR 
99 % 
1.515-1.527 
1.120-1.132 
13.057 
743 
Furfuryl isovalerate O
O
O
 
3283 
10642 
13678-60-9 
Liquid 
C10H14O3 
182.22 
Insoluble 
Miscible 
97-98 (14 hPa) 
 
IR 
98 % 
1.456-1.464 
1.014-1.023 
13.062 
740 
Furfuryl propionate O
O
O
 
3346 
10646 
623-19-8 
Liquid 
C8H10O3 
154.17 
Slightly soluble 
Miscible 
195-196 
 
IR 
98 % 
1.457-1.464 
1.076-1.086 
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Table 1: Specification Summary of the Substances in the Group of furfuryl alcohol and related flavouring substances evaluated by the JECFA (JECFA, 2000d) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
13.067 
742 
Furfuryl octanoate O
O
O
 
3396 
10645 
39252-03-4 
Liquid 
C13H20O3 
224.30 
Insoluble 
Miscible 
139 (13 hPa) 
 
IR 
98 % 
1.456-1.464 
0.980-0.989 
13.068 
741 
Furfuryl valerate O
O
O
 
3397 
10647 
36701-01-6 
Liquid 
C10H14O3 
182.22 
Insoluble 
Miscible 
228-229 
 
IR 
98 % 
1.457-1.462 
1.024-1.031 
13.073 
750 
Octyl 2-furoate O
O
O
 
3518 
10864 
39251-88-2 
Liquid 
C13H20O3 
224.30 
Insoluble 
Miscible 
126-127 (1 hPa) 
 
IR 
98 % 
1.466-1.472 
0.984-0.990 
13.128 
739 
Furfuryl acetate O
O
O
 
2490 
2065 
623-17-6 
Liquid 
C7H8O3 
140.14 
Insoluble 
Miscible 
175-177 
 
IR 
97 % 
1.457-1.466 
1.110-1.119 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95 %  ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
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TABLE 2: GENOTOXICITY DATA  
Table 2.1: Summary of Genotoxicity Data of Furfuryl Derivatives Evaluated by the JECFA (JECFA, 2001b) 
FL-no 
JECFA-no 
EU Register name 
JECFA name 
Structural formula End-point Test system Concentration Results Reference 
13.019 
451 
Furfuryl alcohol 
  
O
OH
 
Reverse mutation  S. typhimurium TA98, TA100, 
TA1535, TA1537 
294 µg/plate Negativea,b (Florin et al., 1980) 
Reverse mutation S. typhimurium TA98, TA100, 
TA1535 
Up to10 000 µg/plate Negativea,b (Mortelmans et al., 1986) 
Reverse mutation S. typhimurium TA100 2500 - 12 500µg/ml  Negativea,b (Stich et al., 1981a) 
Reverse mutation S. typhimurium TA98, TA100, TA102 Up to 198 000 µg/plate Negativea,b (Aeschbacher et al., 1989) 
Reverse mutation S. typhimurium TA98, TA100 81 - 323 µg/plate Negativea,b (Shinohara et al., 1986) 
Reverse mutation  S. typhimurium TA1535, TA100, 
TA1537 (modified assay) 
200 000 µg/ml Positivea,b (McGregor et al., 1981) 
DNA repair and H17 (rec+) B. subtilis M45 (rec–)  2000 - 20 000 µg/disc Positivea,b (Shinohara et al., 1986) 
Sister chromatid exchange  Chinese hamster ovary cells 245 µg/ml Positivea,b (Stich et al., 1981b) 
Sister chomatid exchange Human lymphocytes Up to 196 µg/ml Negative (Jansson et al., 1986) 
Siser chromatid exchange Human lymphocytes Up to 970 µg/ml Negative (Gomez-Arroyo and Souza, 
1985) 
Chromosomal aberration Chinese hamster ovary cells 2000 µg/ml Positive (Stich et al., 1981b) 
Gene conversion  S. cerevisiae strain D7 13 500 - 16 000 µg/ml Positivea (Stich et al., 1981a) 
Sex-linked recessive l lethal 
mutation 
D. melanogaster Up to 6500 ppm by injection Negative (Rodriquez-Arnaiz et al., 
1989) 
Sister chromatid exchange Adult human lymphocytes 32 300 mg/m3 in occupational 
atmosphere 
Negative (Gomez-Arroyo and Souza, 
1985) 
Sister chomatid exchange Adult human lymphocytes 32 300 mg/m3 in occupational 
atmosphere 
Negative (Gomez-Arroyo and Souza, 
1985) 
Chromosomal aberration 
  
Mouse bone-marrow cells  
  
0.5 mg/kg bw in drinking-
water 
1 - 2 mg/kg bw in drinking-
water 
Negative 
Positive 
(Sujatha and Subramanyam, 
1994) 
  
13.128 
739 
Furfuryl acetate O
O
O
Reverse mutation S. typhimurium TA1535, TA98, 
TA100 
33 - 666 µg/plate Positivea,b (Mortelmans et al., 1986) 
13.018 
450 
Furfural O
O
 
Reverse mutation S. typhimurium TA1535, TA100, 
TA1537, TA1538, TA98 
0.1 - 1000 µg/ml Negativea,b (McMahon et al., 1979) 
Reverse mutation 
  
S. typhimurium TA100, TA98, 
TA1535  
Up to 3460 µg/plate  
5766 µg/plate 
Negativea,b 
Positivea (weakly) 
(Loquet et al., 1981) 
  
Reverse mutation S. typhimurium TA100, TA98, TA102 Up to 115 320 µg/plate Negativea,b (Aeschbacher et al., 1989) 
Reverse mutation S. typhimurium TA100, TA98 15 - 63 µg/plate Negativea,b (Shinohara et al., 1986) 
Reverse mutation S. typhimurium TA104 5 - 500 µg/plate Positiveb (Shane et al., 1988) 
Reverse mutation S. typhimurium TA100, TA102  5 - 500 µg/plate Negativeb (Shane et al., 1988) 
Reverse mutation S. typhimurium TA104, TA102 96 µg/plate Negative (Marnett et al., 1985a) 
Reverse mutation S. typhimurium TA98, TA100, 
TA1535 
Up to 6667 µg/plate Negativea,b (Mortelmans et al., 1986) 
Reverse mutation S. typhimurium TA98, TA100 Up to 1000 µg Negativea (Osawa and Namiki, 1982) 
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Table 2.1: Summary of Genotoxicity Data of Furfuryl Derivatives Evaluated by the JECFA (JECFA, 2001b) 
FL-no 
JECFA-no 
EU Register name 
JECFA name 
Structural formula End-point Test system Concentration Results Reference 
Reverse mutation S. typhimurium TA98, TA100, 
TA1535, TA1537  
33 -  6666 µg/plate Negativea,b  
Equivocal in TA100a 
(NTP, 1990a) 
 Furfural (cont.) O
O
 
Reverse mutation S. typhimurium TA100  8000 µg/plate Positivea,b (Zdzienicka et al., 1978) 
Reverse mutation  S. typhimurium TA98 8000 µg/plate Negativea,b (Zdzienicka et al., 1978) 
Reverse mutation S. typhimurium TA100, TA102 100 - 10 000 µg/plate Negativea (Dillon et al., 1998) 
Reverse mutation S. typhimurium TA104 100 - 10 000 µg/plate Equivocala (Dillon et al., 1998) 
Reverse mutation S. typhimurium TA102, TA104 100 - 10 000 µg/plate Negativeb (Dillon et al., 1998) 
Reverse mutation S. typhimurium TA100 100 - 10 000 µg/plate Equivocalb (Dillon et al., 1998) 
Reverse mutation S. typhimurium TA100 (modified 
assay) 
426 µg/plate Negativea,b (Kim et al., 1987b) 
Reverse mutation S. typhimurium TA100, TA1535, 
TA1537 (modified assay) 
200 000 µg/ml Negative (McGregor et al., 1981) 
Reverse mutation E. coli WP2, WP2 uvrA (modified 
assay) 
0.1 - 1000 µg/ml Negativea,b (McMahon et al., 1979) 
SOS induction  S. typhimurium TA1535/ pSK1002 1932 µg/ml Negativea,b (Nakamura et al., 1987) 
DNA repair B. subtilis H17 (rec+) and M45 (rec–) Up to 1000 µg Negativea (Osawa and Namiki, 1982) 
DNA repair B. subtilis H17 (rec+) and M45 (rec–) 0.6 ml Negativea,b (Matsui et al., 1989) 
DNA repair B. subtilis H17 (rec+) and M45 (rec–) 1700 - 17 000 µg/disc Positivea,b (Shinohara et al., 1986) 
Forward mutation L5178Y mouse lymphoma cells, Tk+/– 
locus 
25 - 100 µg/ml 
200 µg/ml 
Negativea 
Positivea 
(McGregor et al., 1988b) 
Sister chromatid exchange Chinese hamster ovary cells 2500 - 4000 µg/ml Positivea,b (Stich et al., 1981b) 
Sister chromatid exchange Chinese hamster ovary cells Up to 1170 µg/ml Positivea,b (NTP, 1990a) 
Sister chromatid exchange Human lymphocytes Up to 0.035 mmol/La 
0.07 -  0.14 mmol/Lc 
Negativea,b 
Positivea,b 
(Gomez-Arroyo and Souza, 
1985) 
Chromosomal aberration Chinese hamster ovary cells 500 µg/ml 
1000 - 2000 µg/ml 
Negative 
Positive 
(Nishi et al., 1989) 
Chromosomal aberration Chinese hamster ovary cells Up to 40 mmol/L  
(3840 mg) 
Positivea,b (Stich et al., 1981b) 
Chromosomal aberration Chinese hamster ovary cells 3000 µg/ml Positive (Stich et al., 1981a) 
Chromosomal aberration Chinese hamster ovary cells Up to 1230 µg/ml Positivea,b (NTP, 1990a) 
Unscheduled DNA synthesis Human liver slices 0.005 - 10 mmol/L  Negative (Adams et al., 1998b) 
Sex-linked recessive lethal 
mutation 
D. melanogaster 1000 mg/kg of diet Negative (Woodruff et al., 1985) 
Sex-linked recessive lethal 
mutation 
D. melanogaster 100 mg/kg by injection Positive (Woodruff et al., 1985) 
Sex-linked recessive lethal 
mutation 
D. melanogaster Up to 6500 mg/kg by injection Negative (Rodriquez-Arnaiz et al., 
1989) 
Chromosomal loss D. melanogaster Oral or injected dose of 3750–
5000 mg/kg of diet. Mated 
with repair-proficient females 
Negative (Rodriquez-Arnaiz et al., 
1992) 
Chromosomal loss D. melanogaster Oral or injected dose of 3750–
5000 mg/kg of diet. Mated 
with repair-deficient females 
Positive (Rodriquez-Arnaiz et al., 
1992) 
Reciprocal trans- location D. melanogaster 100 mg/kg by injection Negative (Woodruff et al., 1985) 
Sister chromatid exchange Mouse bone-marrow cells 50 - 200 mg/kg bw by Negative (NTP, 1990a) 
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Table 2.1: Summary of Genotoxicity Data of Furfuryl Derivatives Evaluated by the JECFA (JECFA, 2001b) 
FL-no 
JECFA-no 
EU Register name 
JECFA name 
Structural formula End-point Test system Concentration Results Reference 
injection 
Spermhead abnormalities Mice 4000 mg/kg of diet daily for 5 
weeks 
Negative (Subramanyam et al., 1989) 
 Furfural (cont.) O
O
 
Somatic chromo-somal 
mutation   
Swiss albino mouse bone- marrow 
cells  
1000 - 2000 mg/kg of diet 
4000 mg/kg bw for 5 days 
Negative 
Positive 
(Subramanyam et al., 
1989)  
Sister chromatid exchange Adult human lymphocytes 9454 mg/m3 in occupational 
atmosphere 
Negative (Gomez-Arroyo and Souza, 
1985) 
Chromosomal aberration Adult human lymphocytes 9454 mg/m3 in occupational 
atmosphere 
Negative (Gomez-Arroyo and Souza, 
1985) 
Unscheduled DNA synthesis B6C3F1 mice  50 - 320 mg/kg bw orally Negative (Edwards, 1999) 
Unscheduled DNA synthesis Fischer 344 rats 5 - 50 mg/kg bw orally Negative (Phillips et al., 1997) 
13.001 
745 
5-Methylfurfural 
 
O
O
 
Reverse mutation S. typhimurium TA1537, TA100, 
TA1535 
288 µg/plate Negativea,b (Florin et al., 1980) 
Reverse mutation S. typhimurium TA98, TA100, TA102  96,100 µg/plate Negativea,b (Aeschbacher et al., 1989) 
Reverse mutation S. typhimurium TA98, TA100 79 - 316 µg/plate Negativea,b (Shinohara et al., 1986) 
DNA repair B. subtilis H17 (rec+) and M45 (rec–) 0.55 - 5500 µg/disk Positivea,b (Shinohara et al., 1986) 
Sister chromatid exchange Chinese hamster ovary cells 2200 - 4070 µg/ml Positivea,b (Stich et al., 1981b) 
a Without metabolic activation from a 9000  g supernatant of rat liver. 
b With metabolic activation. 
C Concentration added to culture. 
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Substances listed in brackets are the JECFA evaluated supporting substances in FGE.13Rev2 
 
TABLE 2.2: GENOTOXICITY (IN VITRO) EVALUATED BY EFSA IN FGE.13REV2 (EFSA, 2011H) 
Chemical Name [FL-no:] Test system Test Object  Concentration Result  Reference  Comments 
Main group I – Non-sulphur-containing Furan Derivatives 
(Furfuryl alcohol [13.019]) Ames test  S. typhimurium TA98, TA100, TA1535 and 
TA1537  
 294 µg/plate  Negative1  (Florin et al., 1980)  
Ames test  S. typhimurium TA98, TA100, TA1535 and 
TA1537 
10000 µg/plate  Negative1 (Mortelmans et al., 1986) 
(NTP, 1999a) 
 
Ames test  S. typhimurium TA100  2500 - 12500 µg/ml  Negative1 (Stich et al., 1981a)  
Ames test  S. typhimurium TA98, TA100 and TA102  198000 µg/plate  Negative1 (Aeschbacher et al., 1989)  
Ames test  S. typhimurium TA98 and TA100  81 - 323 µg/plate  Negative1 (Shinohara et al., 1986)  
Modified Ames test  S. typhimurium TA1535, TA100 and 
TA1537  
200000 µg/ml  Positive1 (McGregor et al., 1981)  
Rec assay  B. subtilis  2000 - 20000 µg/disk  Positive1 (Shinohara et al., 1986)  
Sister chromatid exchange  CHO cells  245 µg/ml  Positive1 (Stich et al., 1981a)  
Sister chromatid exchange  CHO cells  500 µg/ml  Positive/Weakly positive2  
Negative3 
(NTP, 1999a)  
Sister chromatid exchange  Human Lymphocytes  Up to 196 µg/ml  Negative  (Jansson et al., 1986)  
Sister chromatid exchange  Human  
Lymphocytes  
Up to 970 µg/ml  Negative  (Gomez-Arroyo and Souza, 1985)  
Chromosomal aberration  CHO cells  2000 µg/ml  Positive  (Stich et al., 1981a)  
Chromosomal aberration  CHO cells  1600 µg/ml  Negative1 (NTP, 1999a)  
SHE test  Syrian hamster embryo cells  NR Negative3  (Kerckaert et al., 1996)  
Gene Conversion Assay  S. cerevisiae strain D7  13500 - 16000 µg/ml  Positive2 (Stich et al., 1981b)  
Mammalian cell assay  Mouse embryo fibroblast cells (T1) 10 µg/ml  Negative2 (Kowalski et al., 2001)  
p53 – induction assay  Mouse embryo fibroblast cells (NCTC 929)  50 µg/ml  Negative2  (Duerksen-Hughes et al., 1999)  
(Furfuryl acetate [13.128]) Ames test  S. typhimurium TA1535, TA98 and TA100  33 - 666 µg/plate  Positive2  (Mortelmans et al., 1986)  
(Furfural [13.018]) Ames test  S. typhimurium TA1535, TA100, TA1537, 
TA1538, TA98  
0.1 - 1000 µg/ml  Negative1 (McMahon et al., 1979)  
Ames test  S. typhimurium TA100, TA98 and TA1535  Up to 3460 µg/plate  
5766 µg/plate  
Negative1  
Positive2 (weak)  
(Loquet et al., 1981)  
Ames test  S. typhimurium TA100, TA98 and TA102  Up to 115320 µg/plate  Negative1  (Aeschbacher et al., 1989)  
Ames test  S. typhimurium TA100 and TA98  15 - 63 µg/plate  Negative1 (Shinohara et al., 1986)  
Ames test  S. typhimurium TA104 5 - 500 µg/plate  Positive3 (Shane et al., 1988)  
Ames test  S. typhimurium TA100 and TA102  5 - 500 µg/plate  Negative3 (Shane et al., 1988)  
Ames test  S. typhimurium TA104 and TA102 96 µg/plate  Negative  (Marnett et al., 1985a)  
Ames test  S. typhimurium TA98, TA100 and TA1535  Up to 6667 µg/plate  Negative1 (Mortelmans et al., 1986)  
Ames test  S.typhimurium TA98, TA100  Up to 1000 µg  Negative2  (Osawa and Namiki, 1982)  
Ames test  S.typhimurium TA98, TA100, TA1535, 
TA1537  
33 - 6666 µg/plate  Negative1
 TA100  
Equivocal2  
(NTP, 1990a)  
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TABLE 2.2: GENOTOXICITY (IN VITRO) EVALUATED BY EFSA IN FGE.13REV2 (EFSA, 2011H) 
Chemical Name [FL-no:] Test system Test Object  Concentration Result  Reference  Comments 
Ames test  S. typhimurium TA100  8000 µg/plate  Positive1 (Zdzienicka et al., 1978)  
Ames test  S. typhimurium TA98  8000 µg/plate  Negative1  (Zdzienicka et al., 1978)  
Ames test  S. typhimurium TA100, TA102  100 - 10000 µg/plate  Negative2 (Dillon et al., 1998)  
Ames test  S. typhimurium TA104  100 - 10000 µg/plate  Equivocal2 (Dillon et al., 1998)  
Ames test  S. typhimurium TA102, TA104  100 - 10000 µg/plate  Negative3 (Dillon et al., 1998)  
Ames test  S. typhimurium TA100  100 - 10000 µg/plate  Equivocal3 (Dillon et al., 1998)  
Modified Ames test  S. typhimurium TA100  426 µg/plate  Negative  (Kim et al., 1987b)  
Modified Ames test  S. typhimurium TA100, TA1535 and 
TA1537  
200000 µg/ml  Negative  (McGregor et al., 1981)  
Modified Ames test  E. coli WP2 and WP2 uvrA  0.1 - 1000 µg/ml  Negative1 (McMahon et al., 1979)  
SOS induction  S.typhimurium TA1535/ pSK1002  1932 µg/ml  Negative1 (Nakamura et al., 1987)  
Rec-assay  B. subtilis H17 & M45  Up to 1000 µg  Negative  (Osawa and Namiki, 1982)  
Rec-assay  B. subtilis H17 & M45  0.6 ml  Negative1 (Matsui et al., 1989)  
Rec-assay  B. subtilis strains H17 & M45  1700 - 17000 µg/disk  Positive1 (Shinohara et al., 1986)  
Forward mutation assay  L5178Y tk+/- Mouse Lymphoma Cells  25 - 100 µg/ml  
200 µg/ml  
Negative2  
Positive2  
(McGregor et al., 1988b)   
Sister chromatid exchange  CHO cells  2500 - 4000 µg/ml  Positive1  (Stich et al., 1981a)  
Sister chromatid exchange  CHO cells  Up to 1170 µg/ml  Positive1 (NTP, 1990a)   
Sister chromatid exchange  Human  
Lymphocytes  
Up to 0.035 mM4  
0.07 -  0.14 Mm4  
Negative1  
Positive1  
(Gomez-Arroyo and Souza, 1985)   
Chromosomal aberration  CHO cells  500 µg/ml  
1000 - 2000 µg/ml  
Negative  
Positive  
(Nishi et al., 1989)  
Chromosomal aberration  CHO cells  Up to 40 mM (3,840 mg)  Positive1 (Stich et al., 1981a)  
Chromosomal aberration  CHO cells  3000 µg/ml  Positive  (Stich et al., 1981b)  
Chromosomal aberration  CHO cells  375 µg/ml2  
750 µg/ml3  
Positive  (Gudi and Schadly, 1996)  
Chromosomal aberration  CHO cells  Up to 1,230 µg/ml  Positive1 (NTP, 1990a)   
Unscheduled DNA 
Synthesis  
Human liver slices  0.005 - 10 mM  Negative (Adams et al., 1998b)  
DNA-protein cross-links  EBV- human Burkitt’s lymphoma cells  25 mM Positive5 (Costa et al., 1997)  
5-Hydroxymethyl-
furfuraldehyde [13.139] 
Ames test  S. typhimurium TA98; TA100  0.2 - 1 μmol/plate  Negative  (Surh et al., 1994) The study is considered 
valid. Purity 99 %. 
Ames test  S. typhimurium TA98; TA100  0.2 - 2.0 µg/plate  Positive1  (Omura et al., 1983) Posisitive dose related 
respons inTA100 only, most 
potent without S9. Purity 
and other experimental 
details not reported. The 
validity of the study cannot 
be evaluated. 
Ames test  S. typhimurium TA98; TA100  0.17 -  0.66 µmol/plate Positive1  (Shinohara et al., 1986) Positive results only 
obtained in TA100 with S9. 
Reverse dose-respons 
relationship. Experimental 
details are lacking.  
Ames test  S. typhimurium TA104  0.1 - 0.8 mM  Negative2  (Lee et al., 1995b) Positive result was obtained 
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TABLE 2.2: GENOTOXICITY (IN VITRO) EVALUATED BY EFSA IN FGE.13REV2 (EFSA, 2011H) 
Chemical Name [FL-no:] Test system Test Object  Concentration Result  Reference  Comments 
Positive by inclusion of PAPS and 
the rat liver cytosol in the 
assay. The study is 
considered valid. 
Ames test  S. typhimurium TA98; TA100  1 - 50 µl/plate3  Negative1 (Aeschbacher et al., 1981) The study is considered 
valid. 
Ames test  S. typhimurium TA100  4.44 µM/plate  Negative2  (Kim et al., 1987b) Single dose only. 
Ames test  S. typhimurium TA98; TA100; TA1535; 
TA1537  
3 µmol/plate Negative1  (Florin et al., 1980) Spot test. The study is 
considered valid. 
Ames test  S. typhimurium TA100  10 µg/plate  Negative2  (Majeska and McGregor, 1992) The study is considered 
valid. 
Ames test S. typhimurium TA97, TA98, TA102, 
TA1535 
100 - 10,000 µg/plate Negative1 (NTP, 2010c) The study is considered 
valid. 
Ames test S. typhimurium TA100 100 - 10,000 µg/plate Weakly positive2 (NTP, 2010c) The study is considered 
valid. 
Ames test S. typhimurium TA100 and TA98 1,500 - 10,000 µg/plate Negative1 (NTP, 2010c) The study is considered 
valid. 
Ames test S. typhimurium TA98, TA100, TA1535, 
TA1537 
at 0.5 µg/mL up to 5000 
µg/mL 
Negative1 (Severin et al., 2010) For discussion and 
interpretation see text. 
Reverse mutation assay E. coli WP2 uvrA/pKM101 1,500 - 10,000 µg/plate Negative1 (NTP, 2010c) The study is considered 
valid. 
Micronucleus assay HepG2 cells 0, 5.35, 7.87, 11.57, 17, 
25, 36.6 mM 
Negative15 (Severin et al., 2010) For discussion and 
interpretation see text. 
SCE induction V79-hCYP2E1-hSULT1A1 cells 19.8 - 3808 µM Positive (Glatt et al., 2005) For discussion and 
interpretation see text. 
SCE induction V79-Mz cells 238 - 3808 µM, Positive16  (Glatt et al., 2005) For discussion and 
interpretation see text. 
Umu assay  S. typhimurium TA1535  20 mM Positive9  (Janzowski et al., 2000) Positive results were only 
obtained at high 
concentrations resulting in 
reduced cell viability and 
growth. The study is 
considered valid but 
interpretation of data is 
questionable. 
Rec assay  B. subtilis H 17 rec+; M 45 rec-  0.25 - 12.5 mg/disk  Positive1  (Shinohara et al., 1986) Experimental details are 
lacking. The validity of the 
study cannot be evaluated. 
Chromosomal aberration  Chinese hamster V79 cells  Up to 2000 µg/ml  Positive10  (Nishi et al., 1989) Weak positive response 
were only obtained at high 
concentrations. The study is 
considered valid.. 
Comet assay  V79, Caco-2, primary human colon cells 
and primary rat hepatocytes  
Up to 80 mM  Negative2  (Janzowski et al., 2000) The study is considered 
valid but interpretation of 
data is questionable. 
Comet assay HepG2 cells 0, 5.35, 7.87, 11.57, 17, Positive14, 15 (Severin et al., 2010) For discussion and 
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TABLE 2.2: GENOTOXICITY (IN VITRO) EVALUATED BY EFSA IN FGE.13REV2 (EFSA, 2011H) 
Chemical Name [FL-no:] Test system Test Object  Concentration Result  Reference  Comments 
25, 36.6 mM interpretation see text. 
Comet assay Human Caco-2 cells 3,153 - 12,611 µg/mL  
(25 - 100 mM) 
Positive12 (Durling et al., 2009) For discussion and 
interpretation see text. 
Comet assay Human HEK293 cells 3,153 - 12,611 µg/mL  
(25 - 100 mM) 
Positive12 (Durling et al., 2009) For discussion and  
interpretation see text. 
Comet assay Mouse lymphoma L5178Y cells 3,153 - 12,611 µg/mL  
(25 - 100 mM) 
Positive12 (Durling et al., 2009) For discussion and  
interpretation see text. 
Comet assay Chinese hamster V-79  cells 315 - 12,611 µg/mL  
(2.5 - 100 mM) 
Positive13 (Durling et al., 2009) For discussion and  
interpretation see text. 
Comet assay Chinese hamster V-79-hP-PST cells 315 - 12,611 µg/mL  
(2.5 - 100 mM) 
Positive13 (Durling et al., 2009) For discussion and  
interpretation see text. 
HPRT assay  V79 cells  Up to 140 mM  Positive1, 11  (Janzowski et al., 2000) Positive response were only 
obtained at high 
.concentrations resulting in 
reduced cell viability and 
growth. The study is 
considered valid but 
interpretation of data is 
questionable. 
HPRT and tk assay  TK6 human lymphoblast cells  20 - 75 µg/ml  Negative  (Surh and Tannenbaum, 1994)  The study is considered 
valid. 
(5-Methylfurfural [13.001]) Ames test S. typhimurium TA1537, TA100 and 
TA1535  
288 µg/plate  Negative1 (Florin et al., 1980)  
Ames test  S. typhimurium TA98, TA100 and TA102  96100 µg/plate  Negative1 (Aeschbacher et al., 1989)  
Ames test  S. typhimurium TA98 and TA100  79 - 316 µg/plate  Negative1 (Shinohara et al., 1986)  
Rec-assay  B. subtilis strains H17 & M45  0.55 - 5500 µg/disk  Positive1 (Shinohara et al., 1986)  
Sister chromatid exchange  CHO cells  2200 - 4070 µg/ml  Positive1 (Stich et al., 1981a)  
2-Furoic acid [13.136] Ames test  S. typhimurium TA98; TA100  25 - 100 µg/plate  Negative2 (Ichikawa et al., 1986b) The study is considered 
valid. 
Ames test  S. typhimurium TA100   Negative  (Soska et al., 1981) Dose not reported. The 
validity of the study can not 
be evaluated. 
Ames test  S. typhimurium TA100  1000 µg/plate  Negative  (Kitamura et al., 1978) The study is considered 
valid. 
DNA repair test  E. coli WP2l WP2 uvrA; WP67; WP100; 
CM 561; CM 571; CM 611  
1000 µg/disk  Negative  (Soska et al., 1981) The study is considered 
valid. 
Unscheduled DNA synthesis  Primary rat hepatocytes  1000 µg/ml  Negative10, 17  (Aaron et al., 1989) Study performed in 
accordance with GLP. The 
study is considered valid. 
(Methyl-2-furoate [13.002]) Ames test  S. typhimurium TA98; TA100  100 µg/plate  Negative10  (Ichikawa et al., 1986b)  
NR=Not Reported. 
1With and without S9 metabolic activation.  
2 Without S9 metabolic activation.  
3 With S9 metabolic activation. 
4 Concentration added to the culture. 
5 Significant increases in % DNA-protein cross-links occurred only when cell viability was 40 % or less (i.e. high incidence of cell death). 
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6 TA98 with S9 metabolic activation; TA100 without S9 metabolic activation. 
7 5-Hydroxymethylfurfuraldehyde with 0.05 mol L-tryptophan without the presence of nitrite treatment.  
8 5-Hydroxymethylfurfuraldehyde with 0.05 mol L-tryptophan treated with nitrite.  
9 At concentrations of 12 mmol and greater, positive results were obtained without S9 metabolic activation. The dose dependent results were noted at concentrations known to be cytotoxic.  
10 Metabolic activation not reported.  
11 Effects occurred at concentrations inhibiting cellular growth. 
12 Positive only at the highest concentration tested with significant decrease in cell viability. 
13Positive at high concentration with significantly reduced cell viability. 
14Cytotoxic at the two highest doses. 
15 20 hours of exposure. 
16Weakly positive but statistically significant at each concentration. 
17 Dose levels above 300 microgram/ml were cytotoxic.  
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Substances listed in brackets are the JECFA evaluated supporting substances in FGE.13Rev2 
TABLE 2.3: GENOTOXICITY (IN VIVO) EVALUATED BY EFSA IN FGE.13REV2 (EFSA, 2011H) 
Chemical Name [FL-no:] Test system Test Object Route Dose Result Reference Comments 
(Furfuryl alcohol [13.019]) Sex-linked recessive lethal 
test  
D. melanogaster  Injection Up to 6500 ppm  Negative  (Rodriquez-Arnaiz et al., 1989)  
Sister chromatid exchange  Adult Human 
Lymphocytes  
Inhalation 
(occupational 
atmosphere) 
32300 mg/m3  Negative (Gomez-Arroyo and Souza, 1985)  
Chromosomal aberration 
assay  
Adult Human 
Lymphocytes  
Inhalation 
(occupational 
atmosphere) 
32300 mg/m3  Negative (Gomez-Arroyo and Souza, 1985)  
Chromosomal aberration 
assay  
Mouse bone 
marrow cells 
Drinking water 0.5 mg/kg  
1 - 2 mg/kg  
Negative  
Positive  
(Sujatha and Subramanyam, 1994)  
Sister chromatid exchange  Mouse bone 
marrow cells  
IP injection 300 mg/kg  Negative (NTP, 1999a)  
Chromosomal aberration 
assay  
Mouse bone 
marrow cells  
IP injection 300 mg/kg  Negative  (NTP, 1999a)  
Micronucleus assay  Mouse bone 
marrow cells 
IP injection 250 mg/kg  Negative  (NTP, 1999a)  
Mouse bioassay  Tg·AC transgenic 
mice  
Dermal exposure 1.5 mg; 5 days/week for 20 weeks  Negative (Spalding et al., 2000)  
(Furfural [13.018]) 
 
Sex-linked recessive lethal 
test  
D. melanogaster Diet 1000 ppm  Negative  (Woodruff et al., 1985)  
Sex-linked recessive lethal 
test  
D. melanogaster Injection 100 ppm  Positive (Woodruff et al., 1985)  
Sex-linked recessive lethal 
test  
D. melanogaster Injection Up to 6500 ppm  Negative (Rodriquez-Arnaiz et al., 1989)  
Chromosome Loss  D. melanogaster Oral or injected 3750 - 5000 ppm. Mated with repair-
proficient females  
Negative  (Rodriquez-Arnaiz et al., 1992)  
Chromosome Loss  D. melanogaster Oral or injected 3750 - 5000 ppm. Mated with repair-
deficient females  
Positive (Rodriquez-Arnaiz et al., 1992)  
Reciprocal translocations  D. melanogaster Injection 100 ppm  Negative (Woodruff et al., 1985)  
Nondisjunction assay  D. melanogaster 
(females)  
Inhalation 1.5 %  Negative1  (Muñoz and Barnett, 1999)  
Sister chromatid exchange  Mouse bone 
marrow cells  
Injection 50 - 200 mg/kg  Negative (NTP, 1990a)   
Sperm head abnormalities  Mouse Oral 4000 ppm daily for 5 weeks  Negative (Subramanyam et al., 1989)  
Somatic chromosome 
mutations  
Swiss albino 
mouse (bone 
marrow cells)  
 1000 - 2000 ppm  
4000 ppm for 5 days  
Negative  
Positive  
(Subramanyam et al., 1989)  
Sister chromatid exchange  Adult Human 
Lymphocytes  
Inhalation 
(occupational 
atmosphere) 
9454 mg/m3 Negative (Gomez-Arroyo and Souza, 1985)  
Chromosomal aberration 
assay  
Adult Human 
Lymphocytes  
Inhalation 
(occupational 
atmosphere) 
9454 mg/m3 Negative (Gomez-Arroyo and Souza, 1985)  
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TABLE 2.3: GENOTOXICITY (IN VIVO) EVALUATED BY EFSA IN FGE.13REV2 (EFSA, 2011H) 
Chemical Name [FL-no:] Test system Test Object Route Dose Result Reference Comments 
Unscheduled DNA synthesis  Mouse  Oral 50 - 320 mg/kg Negative (Edwards, 1999)  
Unscheduled DNA synthesis  F344 Rat  Oral 5 - 50 mg/kg Negative (Phillips et al., 1997)  
Gene mutation in the λlacZ-
gene in liver 
Transgenic mouse  
CD2F1 (BALB/c x 
DBA/2) 
Oral 75 - 300 mg/kg Negative (CIVO-TNO, 2003)  
5-Hydroxymethylfurfural [13.139] Micronucleus assay Mouse peripheral 
blood cells 
 47, 94, 188, 375 or 750 mg/kg bw/day Negative (NTP, 2010c) 3-months micronucleus 
assay. Limited validity in 
absence of bone-marrow 
toxicity. 
1 Exposure to 1 % solutions did not affect the flies’ behaviour and they had a 95 % survival rate. At dose concentrations of 1.3 and 1.5 % the results indicate a threshold for the induction of nondisjunction.  
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Table 2.4: Genotoxicity on Furfural, SCF Opinion December 2002 (SCF, 2003a) 
Substance End-point Test object Concentration Result Reference 
In vitro 
Furfural [13.018] Reverse mutation S. typhimurium TA100, TA98, TA1535 0.05 - 60 μmol/plate Weakly positive (TA100)b (Loquet et al., 1981) 
S. typhimurium TA100, TA98, TA102 ≤ 1.2 mmol/plate Negativea (Aeschbacher et al., 1989) 
S. typhimurium TA100, TA98 0.165 - 0.660 μmol/plate Negativea (Shinohara et al., 1986) 
S. typhimurium TA102, TA104 5 - 500 μg/plate Positive (TA104) (Shane et al., 1988) 
S. typhimurium TA98, TA100,TA1535, 
TA1537 
33.3 - 6666 μmol/plate Negativea (Mortelmans et al., 1986) 
S. typhimurium TA98, TA100 1 - 15 μL/plate Positivea (TA100) (Zdzienicka et al., 1978) 
S. typhimurium TA98, TA100 7 μL/plate Negativea (Sasaki and Endo, 1978) 
S. typhimurium TA100 4.44 μmol/plate Negativea (Osawa and Namiki, 1982) 
S. typhimurium TA98, TA100, TA104, 
E.coliWP2uvrA/PKM101 
20 μL/plate Negativea (McMahon et al., 1979) 
S. typhimurium TA104 1 μmol (max. non-toxic dose) Negativeb (Marnett et al., 1985a) 
Umu gene expression S. typhimurium TA1535/pSK/1002 1932 μg/mL Negativea (Nakamura et al., 1987) 
Rec assay B.subtilis H17, M45 1.7 - 17 mg/disk Positivea (Shinohara et al., 1986) 
B.subtilis H17, M45 1 mg/disk Negativea (Matsui et al., 1989) 
Forward mutation L5178Ytk+/- mouse lymphoma cells 25 - 800 μg/mL Positiveb (McGregor et al., 1988b) 
Chromosomal aberration Chinese hamster ovary cells 10-40 mM Positivea (Stich et al., 1981a; Stich et al., 
1981b) 
Chinese hamster ovary cells 200 - 1230 μg/mL Positivea (Galloway et al., 1985) 
Chinese hamster ovary cells 1.5 - 5000 μg/mL Positivea (Gudi and Schadly, 1996) 
Chinese hamster V79 cells 500 - 2000 μg/mL Positivea (Nishi et al., 1989) 
Sister chromatid exchange Chinese hamster ovary cells 11.7 - 3890 μg/mL Positivea (Galloway et al., 1985) 
Human peripheral lymphocytes 3.5 - 14x10-5 M Positiveb (Gomez-Arroyo and Souza, 1985) 
Unscheduled DNA 
synthesis 
Human liver slices 0.14 mmol/L 
0-25 mmol/L 
Negative (Lake, 1998) 
In vivo 
 Furfural [13.018] Sex-linked recessive lethal mutation D. melanogaster 1000 ppm, in diet Negative (Woodruff et al., 1985) 
D. melanogaster 100 ppm, by injection Positive (Woodruff et al., 1985) 
Wing spot test D. melanogaster 3750 - 7500 ppm by aerial exposure Positive (Rodriquez-Arnaiz et al., 1989) 
Sex-chromosome loss D. melanogaster 3750 - 5000 ppm, in diet and by 
injection 
Positive on injection (Rodriquez-Arnaiz et al., 1989; 
Rodriquez-Arnaiz et al., 1992) 
Reciprocal translocation D. melanogaster 1000 ppm, in diet Negative (Woodruff et al., 1985) 
Sister chromatid exchange/ chromosomal 
aberration 
B6C3F1 mouse bone marrow cells 50 - 200 mg/kg bw, once i.p. Negative (NTP, 1990a) 
Somatic chromosomal aberration Swiss albino mouse bone marrow cells 4000 ppm for 5 days, in diet Negative (Subramanyam et al., 1989)+ 
Sperm head abnormalities Swiss albino mouse 4000 ppm for 5 weeks, in diet Negative (Subramanyam et al., 1989)+ 
Unscheduled DNA synthesis Fischer 344 rat hepatocytes 5.0, 16.7 or 50 mg/kg bw, orally Negative (Phillips et al., 1997) 
B6C3F1 mouse hepatocytes 50, 175 or 320 mg/kg bw, orally Negative (Edwards, 1999) 
a With and without metabolic activation. 
b Without metabolic activation. 
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+ Aabstract only; no details availabe. 
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TABLE 3: SUMMARY OF SAFETY EVALUATIONS 
Table 3.1: Summary of Safety Evaluation of 14 JECFA-Evaluated Furfuryl Derivatives (JECFA, 2001b) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
 
Class 2) 
Evaluation procedure path 3) 
Outcome on the 
named compound  
[4) or 5)] 
EFSA conclusion on the named 
compound (Procedure steps, 
intake estimates, NOAEL, 
genotoxicity) 
EFSA conclusion on the 
material of commerce 
13.001 
745 
5-Methylfurfural O
O
 
180 
25 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) No safety concern at the estimated 
level of intake based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.002 
746 
Methyl 2-furoate 
O
O
O
 
30 
37 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) No safety concern at the estimated 
level of intake based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.003 
747 
Propyl 2-furoate O
O
O
 
0.061 
0.1 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) No safety concern at the estimated 
level of intake based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.018 
450 
Furfural O
O
 
440 
460 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) No safety concern at the estimated 
level of intake based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.019 
451 
Furfuryl alcohol O
OH
 
180 
24 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) No safety concern at the estimated 
level of intake based on the MSDI 
approach.  Separate EFSA opinion 
available. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.057 
743 
Furfuryl isovalerate O
O
O
 
0.024 
1 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) No safety concern at the estimated 
level of intake based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.062 
740 
Furfuryl propionate O
O
O
 
1.7 
5 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) No safety concern at the estimated 
level of intake based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.068 
741 
Furfuryl valerate O
O
O
 
0.24 
14 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) No safety concern at the estimated 
level of intake based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.128 
739 
Furfuryl acetate O
O
O
 
16 
21 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) No safety concern at the estimated 
level of intake based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.005 
749 
Hexyl 2-furoate O
O
O
 
0.061 
0.1 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) No safety concern at the estimated 
level of intake based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
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Table 3.1: Summary of Safety Evaluation of 14 JECFA-Evaluated Furfuryl Derivatives (JECFA, 2001b) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
 
Class 2) 
Evaluation procedure path 3) 
Outcome on the 
named compound  
[4) or 5)] 
EFSA conclusion on the named 
compound (Procedure steps, 
intake estimates, NOAEL, 
genotoxicity) 
EFSA conclusion on the 
material of commerce 
13.025 
748 
Pentyl 2-furoate O
O
O
 
0.36 
0.1 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) No safety concern at the estimated 
level of intake based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.038 
752 
2-Phenyl-3-carbethoxyfuran 
O
O
O
0.012 
2 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) No safety concern at the estimated 
level of intake based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.067 
742 
Furfuryl octanoate O
O
O
 
0.012 
6 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) No safety concern at the estimated 
level of intake based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.073 
750 
Octyl 2-furoate O
O
O
 
2.2 
0.1 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) No safety concern at the estimated 
level of intake based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
ND: not determined. 
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Table 3.2: Summary of Safety Evaluation Applying the Procedure for 10 Furfuryl Derivatives of FGE.13Rev2 (REF:6915) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day) 
Class 2) 
Evaluation procedure path 3) 
Outcome on the named 
compound [ 4) or 5] 
Outcome on the material 
of commerce [6), 7), or 8)] 
Evaluation 
remarks 
13.122 
 
Ethyl 2-furoate O
O
O
0.39 
 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
13.130 
759 
Furfuryl butyrate 
O
O
O 0.24 
 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
13.136 
 
2-Furoic acid 
O
OH
O 0.013 
 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
13.139 
 
5-Hydroxymethylfurfuraldehyde O
OHO
0.39 
 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
13.011 
 
Ethyl furfuracrylate 
O
O
O 0.12 
 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
13.102 
 
Butyl 2-furoate O
O
O
0.12 
 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
13.127 
 
Furfuryl 2-methylbutyrate 
O
O
O
0.73 
 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
13.129 
 
Furfuryl but-2-enoate O
O
O
0.11 
 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
13.132 
 
Furfuryl hexanoate O
O
O
0.58 
 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
13.133 
 
Furfuryl isobutyrate 
O
O
O
0.89 
 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) 6)  
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
6) No safety concern at estimated level of intake of the material of commerce meeting the specification of Table 1 (based on intake calculated by the MSDI approach). 
7) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or information on stereoisomerism. 
8) No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
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ABBREVIATIONS 
ADI  Acceptable daily intake  
BMDL,  Benchmark Dose (Lower Confidence Limit). 
BW  Body weight 
CAS  Chemical Abstract Service 
CEF  Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
CHO  Chinese hamster ovary (cells) 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
EFSA  The European Food Safety Authority 
ENU  Ethylnitrosourea  
EPA  United States Environmental Protection Agency  
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
GLP  Good laboratory practice 
GSH  Glutathione 
HMF  Hydroxymethylfurfualdehyde 
HPRT  Hypoxanthine phosphoribosyltransferase 
ID  Identity 
Ip  Intraperitoneal 
IR  Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
NCE  Normochromatic erythrocyte 
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No  Number 
NOAEL No observed adverse effect level 
NOEL  No observed effect level 
NTP  National Toxicology Program 
OECD  Organisation for Economic Co-operation and Development 
PAPS  3'-Phosphoadenosine-5'-phosphosulfate 
PCE  Polychromatic erythrocyte 
PFU  Plaque-forming units  
SCE  Sister chromatic exchange 
SCF  Scientific Committee on Food 
UDS  Unsheduled DNA Synthesis 
WHO  World Health Organisation 
